

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.

(19)



Europäisches Patentamt

European Patent Office

Office européen des brevets



(11)

EP 1 035 209 A1

(12)

EUROPEAN PATENT APPLICATION

(43) Date of publication:
13.09.2000 Bulletin 2000/37

(51) Int Cl.7: C12N 15/86, C12N 7/01,
C12N 5/10, A61K 39/00,
A61K 39/145, A61K 48/00

(21) Application number: 99104519.6

(22) Date of filing: 06.03.1999

(84) Designated Contracting States:
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE
Designated Extension States:
AL LT LV MK RO SI

(71) Applicant: ARTEMIS Pharmaceuticals GmbH
51063 Köln (DE)

(72) Inventors:
• Hobom, Gerd
35392 Giessen (DE)

• Flick, Ramon
13793 Västerhaninge (SE)
• Menke, Anette
35037 Marburg (DE)
• Azzey, Mayra
35394 Giessen (DE)

(74) Representative:
Helbing, Jörg, Dr. Dipl.-Chem. et al
Patentanwälte
von Kreisler-Selting-Werner,
Postfach 10 22 41
50462 Köln (DE)

(54) Stable recombinant influenza viruses free of helper viruses

(57) The invention relates to a recombinant influenza virus for high-yield expression of incorporated foreign gene(s), which is genetically stable in the absence of any helper virus; wherein

- (a) at least one of the regular viral RNA segments has been exchanged for a vRNA encoding a foreign gene; and/or
- (b) at least one of the regular viral RNA segments is an ambisense RNA molecule, containing one of

the standard viral genes in sense orientation and a foreign, recombinant gene in antisense orientation, or vice versa, in overall convergent arrangement.

The present invention further provides a method for the production of said recombinant influenza virus, a method for constructing specific ribozyme-sensitive influenza carrier strains; pharmaceutical compositions comprising said recombinant influenza virus; and the use of said recombinant influenza virus for preparing medicaments for vaccination purposes.

Description

- [0001] The invention relates to a recombinant influenza virus for high-yield expression of incorporated foreign gene(s), which is genetically stable in the absence of any helper virus; a method for the production of said recombinant influenza virus, a method for constructing specific ribozyme-sensitive influenza carrier strains; pharmaceutical compositions comprising said recombinant influenza viruses; and the use of said recombinant influenza virus for preparing medicaments for vaccination purposes.
- [0002] Redesigning influenza virus into a vector system for expression of foreign genes similar to what has been achieved in several other thoroughly studied viruses such as adenovirus, retrovirus, Semliki Forest virus or Rabies virus has the advantage of an industrially well established mode of cheap propagation for influenza in fertilized chicken eggs leading to rather high titers (above 10^{10} /ml). On the other hand none of its genes may be deleted from the influenza genome according to our present knowledge, and give room for large-size foreign insertions. Only small fragments of foreign polypeptide chains such as B cell epitopes (10 to 15 amino acids) may be inserted into selected positions within two of the viral proteins, i.e. in exchange for one of the variable antigenic regions located at the surface of hemagglutinin (Muster et al., Mucosal model of immunization against human immunodeficiency virus type 1 with a chimeric influenza virus. *J. Virol.* 69 (11), 6678-6686 (1995)), or into the stalk sequence of viral neuraminidase (Garcia-Sastre and Palese, The cytoplasmic tail of the neuraminidase protein of influenza A virus does not play an important role in the packaging of this protein into viral envelopes. *Virus Res.* 37, 37-47 (1995)), and be stably maintained as functional fusion proteins. Constructs of this kind turned out to be useful for experimental vaccination in a few cases studied, but only rather few clearly defined epitope sequences (of ten to twelve amino acids each) are known today, and some of them might also be misfolded within such restricted fusion protein positions, or in other cases interfere with the correct tertiary structure and function of their host polypeptide chains.
- [0003] Incorporation of a full-size foreign protein into influenza via reverse genetics, encoded by an independent ninth vRNA molecule in addition to its regular set of eight standard vRNA segments is without special provisions only transiently possible (Luytjes et al., Amplification, expression, and packaging of a foreign gene by influenza virus. *Cell* 59, 1107-1113 (1989); Enami et al., An influenza virus containing nine different RNA segments. *Virology* 185, 291-298 (1991)). In the absence of a continuous selective pressure any additional recombinant vRNA segment cannot be stably maintained as long as a wildtype promoter sequence is used on that ninth vRNA segment, and it will inadvertently be lost after few steps of propagation. Using a different system of influenza reverse genetics developed in our laboratory (Zobel et al., RNA polymerase I catalysed transcription of insert viral cDNA. *Nucleic Acids Res.* 21, 3607-3614 (1993); Neumann et al., RNA polymerase I-mediated expression of influenza viral RNA molecules. *Virology* 202, 477-479 (1994)), which was built around *in vivo* synthesis of recombinant vRNA molecules by cellular RNA polymerase I transcription of the respective template cDNA constructs, promoter-up mutations have been designed by nucleotide substitutions (Neumann and Hobom, Mutational analysis of influenza virus promoter elements *in vivo*. *J. Gen. Virol.* 76, 1709-1717 (1995)). When these are attached to a recombinant ninth vRNA segment its increased transcription and amplification rate will not only compensate for the losses suffered spontaneously, but even cause accumulation of the foreign vRNA segment during simple viral passaging, in the absence of any selection. However, due to its over-replication relative to all of the regular influenza vRNA segments (which of course are connected to wild-type promoter sequences) after catching up with the others the foreign segment will become over-abundant. This increasingly will result in viral particles that have incorporated several copies of recombinant vRNA, but no longer have a full set of all eight standard segments incorporated among an average of about 15 vRNA molecules present within a virion. Such particles are defective and will not result in plaque formation, hence after an initial increase of recombinant viral particles during the first steps of propagation a dramatic decrease is observed, usually at the third or fourth step of viral passaging, depending on the size of the recombinant vRNA and the level of the promoter-up mutation attached. A balanced situation with regard to the insert length and the level of promoter activity can be achieved, and has been propagated in a particular case over 11 passages, with essentially stable levels of recombinant viruses among a majority of helper viruses (around 80%) during these steps. If a full-level promoter-up mutation is used (1104 or the new variant 1920, see below) a balanced-level propagation is reached in conjunction with a recombinant vRNA size of 4000 nucleotides (unpublished):
- [0004] In all of these preparations, both in transiently achieved increased yields (up to 40% of recombinants after three or four steps of viral passage), and in a balanced propagation of recombinant influenza viruses (10 - 20%) the respective viral progeny inadvertently constitute mixtures with a majority of non-recombinant helper viruses. These result both from a statistical mode of packaging vRNA molecules into a virion (the ninth segment may not be co-packaged), and from the fraction of cells solely infected by helper virus. The problems of fractional yields and of instability during viral propagation of recombinant influenza are the problems to be solved with the present invention.
- [0005] Starting out from two observations in this laboratory which are discussed below and which concern two hitherto unsuspected properties of influenza viral RNA polymerase in its interaction with terminally adapted influenza-specific RNA molecules, a new technique for the construction of stable recombinant influenza viruses was found.

[0006] As previously described in WO 96/10641 plasmid constructs are designed to generate influenza vRNA-like molecules *in vivo* by cellular RNA polymerase I transcription following plasmid DNA transfection into tissue culture cells, and to this end contain flanking rDNA promoter and terminator elements, externally located relative to any cDNA constructs in between. The resulting recombinant vRNA molecules are designed to contain 5' and 3' recognition sequences for influenza viral RNA polymerase, which however carry up to five nucleotide substitutions (in promoter-up mutant pHL1920) resulting in a substantial increase of expression over wildtype influenza promoter levels. While recombinant pseudoviral RNA is initially transcribed by RNA polymerase I, further amplification and mRNA transcription depends on the presence of viral RNA polymerase and viral nucleoprotein in the cell, which generally are provided by infection of a helper virus. As a consequence the progeny viral yield will constitute a mixture of recombinant viruses together with a majority of wild-type helper viruses.

[0007] In the new technique the recombinant vRNA-like molecules as transcribed by RNA polymerase I are constructed as ambisense RNA double segments, with one reading frame (an influenza gene) in sense and a second one (a foreign gene) in anti-sense orientation, or vice versa. In such constructs both reading frames will be expressed via the cap-snatching mode, even if at different levels. Again, infection by helper virus is required to provide the necessary viral early and late proteins for genetic expression and virion packaging. However, the particular helper virus used in the new method is a recombinant virus carrying 2x2 specifically designed ribozyme targets inserted into the flanking non-coding sequences of one of its eight vRNA segments. The viral segment chosen to become ribozyme-sensitive is always identical to the one used in constructing the recombinant ambisense RNA molecule, as the viral carrier gene in covalent linkage with an additional foreign gene.

[0008] Recombinant influenza viruses produced in this way through RNA polymerase I transcription of an ambisense viral RNA molecule followed by infection with that specifically designed type of ribozyme-sensitive helper virus will carry one of the influenza genes twice, once within that ribozyme-sensitive helper vRNA segment, and a second time within the ribozyme-resistant ambisense segment. Recombinant viruses of this type are again obtained initially only as a mixture together with a majority of non-recombinant helper viruses. A progeny viral passage through tissue culture cells (293T) which before have been transiently transfected with plasmid constructs expressing the respective double-headed ribozyme will (in one step) inactivate the ribozyme-sensitive segment by a factor of up to 100. One or two rounds of such ribozyme treatment *in vivo* will at the same time (a) purify the recombinant virus from its non-recombinant helper contaminants, and (b) delete the sensitive vRNA helper segment from within the initial (additive) recombinant virus.

[0009] As a result recombinant influenza viruses are isolated along this several-step procedure, which are free of contaminating helper viruses and carry seven regular and one ambisense vRNA segments, all in a balanced replication mode. Their recombinant nature is stably maintained because of a covalent junction between one of the viral genes and the full-size foreign gene inserted, a situation achieved here for the first time, via constructing an influenza ambisense RNA segment. The whole procedure is independent of any (selectable) phenotype, and can be applied to either of the eight influenza vRNA segments. After establishing a first ambisense vRNA segment carrying a single foreign gene it can also be repeated all over for inserting a second foreign gene within another ambisense RNA segment of the same constitution in principle.

[0010] Stable recombinant viruses of the type described can be used for cheap propagation in fertilized eggs, either for production of those recombinant viruses themselves or for production of foreign proteins or glycoproteins encoded by them, and hence find application in (glyco)protein production or in providing vector systems for somatic gene therapy or in being used as vaccination agents.

[0011] Thus, the present invention provides

(1) a recombinant influenza virus for high-yield expression of incorporated foreign gene(s), which is genetically stable in the absence of any helper virus, wherein

(a) at least one of the regular viral RNA segments has been exchanged for a vRNA encoding a foreign gene; and/or
 (b) at least one of the regular viral RNA segments is an ambisense RNA molecule, containing one of the standard viral genes in sense orientation and a foreign, recombinant gene in anti-sense orientation, or vice versa, in overall convergent arrangement;

(2) a method for the production of recombinant influenza viruses as defined in (1) above comprising

(a) RNA polymerase I synthesis of recombinant vRNAs *in vivo*, in antisense, sense or ambisense design,
 (b) followed by infection with an influenza carrier strain constructed to include flanking ribozyme target sequences in at least one of its viral RNA segments, and
 (c) thereafter selective vRNA inactivation through ribozyme cleavage;

(3) a method of constructing influenza carrier strains carrying one or more ribozyme target sites (of type one) in vRNA flanking positions comprising

5 (a) RNA polymerase I synthesis of recombinant vRNAs *in vivo*, carrying two different 3' promoter sequences in tandem, which are separated by a second type of ribozyme target sequence, and which carry the said internal ribozyme target sites of type one;

(b) followed by infection of an influenza wildtype strain;

(c) thereafter amplification through simple steps of viral propagation; and

10 (d) finally isolation through removal of their external 3' promoter sequence by ribozyme cleavage through infection of cells expressing ribozyme type 2, followed by plaque purification;

said method being suitable for the construction of an influenza carrier strain required for step (b) of (2) above;

(4) a ribozyme-sensitive influenza carrier (helper) strain obtainable by the method of (3) above;

(5) a pharmaceutical composition comprising a recombinant virus as defined in (1) above;

15 (6) use of a recombinant virus as defined in (1) above for preparing a medicament for vaccination purposes;

(7) use of a recombinant virus as defined in (1) above as vector systems in somatic gene therapy, for transfer and expression of foreign genes into cells (abortively) infected by such viruses, either in *ex vivo* or *in vivo* application schemes; and

20 (8) a method for the production of proteins or glycoproteins which comprises utilizing a recombinant influenza virus as defined in (1) above as expression vector.

[0012] Moreover, the invention provides a method for preventing/treating influenza utilizing a recombinant virus as defined in (1) above, i.e., a vaccination method utilizing said recombinant virus.

[0013] According to the present invention "influenza virus" embraces influenza A virus, influenza B virus and influenza C virus. A preferred recombinant virus of the invention is where one or both of the standard glycoproteins hemagglutinin and neuraminidase have been exchanged into foreign glycoprotein(s) or into fusion glycoproteins consisting of an anchor segment derived from hemagglutinin and an ectodomain obtained from the foreign source, viral or cellular, or in which such recombinant glycoprotein has been inserted as a third molecular species in addition to the remaining standard components.

[0014] Further preferred recombinant viruses of the invention are where the terminal viral RNA sequences, which are active as the promoter signal, have been varied by nucleotide substitutions in up to five positions, resulting in improved transcription rates of both the vRNA promoter as well as the cRNA promoter as present in the complementary sequence.

[0015] Further preferred embodiments of the invention are set forth herein below.

A. Construction of influenza helper virus strains carrying ribozyme target sequences in flanking positions within either of the vRNA segments

[0016] A.1. Influenza RNA polymerase will initiate transcription and replication from promoter structures located at internal positions in an RNA molecule, not only from the natural position at both ends of a vRNA molecule:

[0017] This is true in particular for promoter-up variants in RNA-internal location due to their enhanced binding affinity for viral polymerase. Not only 3' end extensions are tolerated in RNA-internal promoter recognition (Fig. 1), but also 5' extensions as well as extensions at both ends of the RNA template molecule, containing noncomplementary as well as complementary sequence, i.e. potentially present as a double-stranded extension. Finally, also an extension by way of duplication of the promoter sequence (active or inactivated) leads to mRNA transcription and CAT expression, initiated from the active pair of 5' and 3' promoter halves, irrespective if in external or in internal or even in an oblique localization (active 5' promoter sequence in external, active 3' promoter sequence in internal position, or vice versa). RACE-determination of the resulting 5' and 3' ends of viral mRNA and cRNA, i.e. the products of transcription and replication reactions for several of the extended template vRNA constructs proves an exact recognition and sequence-specific initiation at a position equivalent to regular 3' position 1: all of the various template extensions are lost in every product RNA molecule, most likely after only one round of replication.

[0018] A.2. Bicistronic (tandem) vRNA molecules carrying an additional 3' specific promoter sequence in a central position between its two genes can be used for an indirect selection method for recombinant influenza viruses:

[0019] The method described is applicable for any foreign gene (e.g. CAT) without a selection potential of its own, if inserted into the distal mRNA position (proximal vRNA position, in anti-sense orientation) behind a carrier gene (e.g. GFP) in the proximal mRNA position, able to serve as a transient selection marker. The carrier gene which is used for selection will get lost spontaneously during further propagation. These constructs are equivalent to a 3' extension of the template vRNA by a full-size gene of 750 nucleotides up to a second 3' promoter sequence, in terminal location.

While in the set of experiments shown in Fig. 2 the external 3' promoter sequence is maintained throughout as the same promoter-up variant (1104), the internal 3' promoter sequence has been varied to include a full-level promoter-up variant (pHL2270, containing promoter mutant 1104), a medium-level promoter variant (pHL2350, promoter mutant 1948), a wildtype promoter construct (pHL2629), and a construct carrying an unrelated central sequence in an otherwise identical design (pHL2300).

[0020] Due to the presence of two 3' promoter sequences in conjunction with a single 5' promoter sequence an alternating interaction between them will constitute one or the other active promoter structure (see Fig. 3). While the external location with an adjacent RNA 3' end may have a structural advantage, this appears to be compensated by the shorter distance in an interaction between the 5' sequence and the central 3' sequence in constituting the internal promoter, such that the competition between the two primarily reflects the various internal 3' promoter allele sequences used, compare Fig. 2B and activity ratios indicated above and below the lanes. Translation of the mRNA-distal gene (CAT) is only observed following an internal initiation at the bicistronic vRNA template, resulting in a spontaneous deletion of the mRNA-proximal (vRNA-distal) gene, GFP, compare right half of Fig. 3. In complementary analyses GFP fluorescence is observed initially for all of the bicistronic constructs, but gets lost on a faster rate from pHL2270 transfected and influenza infected cells (not shown), and will stay unchanged in pHL2300-treated cells. The indirect selection system based on bicistronic (tandem) molecules as designed here and demonstrated for reporter genes GFP and CAT can be used for any other gene without distinct phenotype upon insertion behind an unrelated carrier gene with properties useful in selection. - In employing that technique an initial phase of (repeated) positive selection for infected cells expressing that proximal trait (e.g. by FACS or by magneto-beads) will be followed by a second phase with negative selection, i.e. against that fraction of infected cells still exposing the same property.

[0021] A.3. Isolation of an influenza strain designed to carry 2x2 flanking ribozyme target sequences at the 5' and 3' end of vRNA segment 4 coding for hemagglutinin:

The above scheme for an indirect selection of any foreign recombinant gene behind a proximal carrier gene is further modified by deleting the carrier gene altogether. Instead, both 3' terminal promoter sequences (mutant and wildtype) follow each other at a short distance, separated only by a specific, repetitive ribozyme target sequence, - different from other target sequences to be described further below. The cDNA insert following after the second 3' promoter sequence consists mainly of a regular hemagglutinin (H7) coding sequence, however both the 5' and 3' vRNA terminal regions of the insert carry that other ribozyme target sequence (different from the first target sequence mentioned above) inserted in either location in tandem duplication (pHL2969, see Fig. 14).

[0022] Due to a superior replication supported by the promoter-up variant located in 3' external position the recombinant HA segment attached to that promoter sequence will become enriched during the first steps of viral propagation, while the originally dominating HA segment of the helper virus which is under control of a wildtype promoter sequence is consecutively reduced and finally is no longer detectable among viral progeny. This result is documented by RT-PCR analysis of consecutive viral populations as obtained in that stepwise propagation procedure, see Fig. 4.

[0023] In the next step the viral lysate is twice passaged via infection of cell culture cells (293T) that before have been DNA-transfected by plasmid pAM403 (Fig. 15). This construct has been specifically designed to express a hammerhead ribozyme with flanking sequences complementary to the repetitive GUC-containing target sequence, as present twice in between the external and internal 3' promoter signals in the recombinant HA vRNA segment, see Fig. 5. In this way the extra promoter sequence is cut off from the finally resulting recombinant HA vRNA. Its promoter-up activity was useful in achieving an initial increase in the concentration of recombinant HA vRNA over wildtype HA vRNA, and in finally excluding the latter from further propagation. However, for the same reason that high activity of the promoter variant will cause instability in the resulting viral progeny, and an effective 'substitution' at this time through ribozyme cleavage by the internally located promoter signal, wild-type or slightly improved, will restore stability to the progeny viruses, with all of their eight vRNA segments now brought back in balance to each other. Due to the ribozyme cleavage site at 26 nucleotides 3' of the wild-type promoter sequence (see Fig. 5), in the initial stage that promoter signal is situated in a vRNA-internal location, extended by a 3' terminal sequence of 26 nucleotides. According to the data presented in Fig. 1 this should cause a transient slight reduction in activity, resulting however in one step in regular viral mRNAs and cRNAs, with any initially remaining extra sequence being lost from the finally resulting recombinant HA vRNA.

[0024] Progeny viruses still carrying an external promoter-up sequence (before ribozyme treatment or due to incomplete reaction) will not cause any plaque, due to over-replication of one vRNA segment relative to all others which results in a high load of defective particles. However, progeny viruses which have lost that external promoter element due to ribozyme cleavage will yield regular plaques due to a balanced mode of replication for all eight wild-type or recombinant vRNA segments. Hence plaque purification is used for isolating a pure influenza viral strain carrying 2x2 ribozyme targets in its recombinant HA vRNA segment, with its termini reduced to the wild-type promoter sequence. The nature of the viral strain isolated has been confirmed in this regard by RT-PCR analysis, see Fig. 4.

[0025] The above isolation procedure resulting in influenza viral strains carrying 2x2 flanking ribozyme target sequences has been performed twice for the HA coding segment (segment 4) to obtain two different isolates with regard

to the orientation of the ribozyme target sequences. In one of the isolates (vHM41, see SEQ. ID NO: 3) the tandem target sites have been inserted into the HA vRNA non-translated sequence both in 5' and 3' location, while according to the second design that 5' tandem target sequence has been included in an inverted orientation, such that it is now present in the cRNA 3' sequence instead (vHM42).

[0026] In another experiment the same procedure was used to isolate an influenza strain carrying 2x2 tandem target sites within the 5' and 3' flanking positions of segment 8 vRNA, i.e. coding for genes NS1 and NS2 (vHM81; see SEQ. ID NO:4). And in principle the same could be done for any other influenza segment, in particular since only the reading frame cDNA sequence has been exchanged from HA to NS, with all of the flanking elements directly responsible for that procedure remaining in place, unchanged.

[0027] A.4. Ribozyme cleavage and vRNA segment exchange using ribozyme-sensitive influenza strains as helper viruses:

In an initial model experiment a range of ribozyme type and target site locations was probed in designing a series of CAT reporter gene vRNA constructs (analysed in the presence of a surplus of wildtype helper virus) in 293T cells. While all of the ribozyme constructs adhered to the hammerhead model, with 10 to 12 nucleotides of complementary

-sequence flanking on either side of the GUC target site, these ribozyme constructs varied from monomer to dimer to trimer repetitions. Ribozyme containing mRNAs were synthesized *in vivo* via the basic vector plasmid pSV2-neo, i.e. using the efficient p_{SV2} RNA polymerase II promoter element for expression, and the SV40 origin signal for plasmid amplification, in a cell line (293T or cos-1) with an incorporated SV40 T antigen gene. In addition the pSV2-neo mRNA includes the small, 63 nucleotide intron sequence of the SV40 early mRNA which is supposed to be spliced very slowly,

thereby extending the pre-mRNA half-life in the nucleus. Each of the pSV2-neo-ribozyme plasmid constructs was transfected into 293T cells. Thereafter, recombinant viruses containing dimer target sites either near one end of the molecule only, or near both ends have been used for infection of the transfected cells. Relative activities of ribozyme constructs versus vRNA target sites have been measured via inactivation of CAT acetyl transfer rates in the cell lysates obtained at 8 h post infection (Fig. 6). The highest activities were observed for dimer ribozymes acting on vRNA molecules carrying 2x2 target sequences on both ends of the molecule, either in vRNA 5' and 3' location, or in vRNA 3' and cRNA 3' location, i.e. with an inversion of the target site sequence at the vRNA 5' end. Consequently, the two constructs carrying tandem ribozyme double targets within both of their non-translated vRNA flanking sequences have been used in the design of ribozyme-sensitive influenza virus strains as described above, with both variants isolated for segment 4 (HA), and one of them for segment 8 (NS). In complementary correspondence the hammerhead ribozyme

plasmid used has also been constructed as a double-headed structure with flanking sequences as shown in Fig. 7 (pAM424; for its detailed structure, see Fig. 16).

[0028] The three target site-containing influenza strains isolated as described above have been analysed for their sensitivity against ribozyme cleavage by infection of 293T cells, which had been DNA-transfected 18 h earlier by ribozyme-producing plasmid pAM424, at DNA-transfection rates between 60 and 70 % (as observed in parallel transfections using GFP-expressing plasmid pAM505). Inactivation rates in these one-step control experiments were between 90% and 99% for all three ribozyme-sensitive strains, in their extent mainly depending upon the actual DNA-transfection rates achieved in individual experiments.

In the next step both isolates of HA-coding ribozyme-sensitive viruses, vHM41 and vHM42, have been used in marker-rescue experiments. Here, 293T cells have been first DNA transfected by HA-variant cDNA construct pH2507 (see Fig. 17), followed after 18 h by vHM41 or vHM42 virus infections at moi 1. The resulting viral supernatant containing e.g. a mixture of ribozyme-sensitive vHM41 carrier virus and pH2507/vHM41 recombinant virus is propagated in an intermediate step on MDCK cells, which also results in an increase in the fraction of recombinant viruses. Thereafter the resulting virus-containing supernatant is passaged through 293T (or cos-1) cells, which in advance have been transiently transfected by ribozyme-producing pAM424. As may be concluded from the above experiment (Fig. 6) and shown in Fig. 8 vHM41- or vHM42-derived ribozyme-sensitive HA vRNA segments are expected to be inactivated by pAM424-produced ribozyme down to a remaining level of about 1% to 10% (mainly present within cells that are infected, but not DNA-transfected).

[0029] Instead, the substitute HA vRNA which originated from pH2507 plasmid DNA (ribozyme-resistant) becomes exclusively incorporated into progeny virions. For further purification and viral propagation these have been passaged a second time through 293T cells, again in advance DNA-transfected by pAM424, and after another amplification step on MDCK cells the resulting viral preparations have been used for RT-PCR analysis. The resulting viral populations in these marker rescue experiments only contain HA-vRNA molecules derived from pH2507, which in their PCR analyses are of intermediate size relative to wildtype HA-vRNA, and vHM41- or vHM42-derived HA-vRNAs, respectively.

[0030] Consequently, a set of ribozyme-sensitive influenza strains with targets inserted individually into every vRNA molecule may be used for such one-step marker rescue experiments in general, i.e. for vRNA segment exchange reactions performed in a directional way for any of the eight influenza vRNA segments, without requirement for a selectable change in phenotype (genetic marker).

B. Expression of two gene products from ambisense bicistronic influenza vRNA

[0031] B.1. The influenza cRNA promoter is active in antisense viral mRNA transcription according to the cap-snatching mode of initiation:

5 While the vRNA template of influenza virus is known to be active in viral mRNA as well as cRNA synthesis, the cRNA template has been described so far only to produce vRNA molecules, as a second step in viral replication. The potential activity of the cRNA promoter in initiating also viral mRNA transcription has not been analysed or even suspected so far, since no antisense (vRNA) reading frame can be detected in any of the viral RNA segments. Also, no U₅/U₆ template sequence element is present in any of the viral cRNAs in an adjacent position to its 5' promoter structure as is the case
10 for all viral vRNAs. This element is known to serve as a template sequence for mRNA terminal poly-adenylation, in repetitive interaction. However, when both elements are provided through reconstruction of an artificial influenza cRNA segment: a reading frame in opposite orientation (CAT), and a U₆ template element in 5' adjacent location, CAT expression can indeed be observed, see pH2583 (see Fig. 18) in Fig. 9. Similar to the vRNA promoter the cRNA promoter activity is improved by (the same) promoter-up mutations, which essentially consist of basepair exchanges according
15 to the 'corkscrew' model. This model apparently also holds for the cRNA promoter structure as analysed in a stepwise manner in Fig. 9. While the cRNA promoter has to be superior over the vRNA promoter in its initiation of replication, since the vRNA/cRNA product ratio was determined to be around 10:1 (Yamanaka et al., *In vivo* analysis of the promoter structure of the influenza virus RNA genome using a transfection system with an engineered RNA. Proc. Natl. Acad. Sci. USA 88, 5369-5373 (1991)), the cRNA promoter is observed to be inferior to the vRNA promoter in its initiation
20 rate of transcription (compare pH2583 with pH1844 in Fig. 9), at least for all promoter variants tested so far.

[0032] A RACE analysis for determination of the 5' ends in pH2583 cRNA promoter transcribed mRNAs proved this initiation to occur according to the cap-snatching mode, in complete equivalence to standard vRNA promoter controlled transcription initiation.

[0033] B.2. Development of ambisense influenza constructs for consecutive expression of two genes (GFP and CAT) from a single viral RNA:

For a bidirectional transcription and translation of influenza RNA segments the two reporter genes GFP and CAT have been arranged in opposite orientation to each other, and the flanking 5' and 3' promoter sequences (adhering to promoter-up variant 1104) had to be reconstructed to include a U₆ poly-adenylation element in either orientation in a 5' promoter adjacent position. This requirement necessarily resulted in a promoter-adjacent 5'-U₆/3'-A₆ complementary structure, both in the vRNA and cRNA terminal sequence (see Fig. 10), which had to be tested for its promoter activity, in either orientation. Therefore, the convergent pair of reporter genes GFP and CAT has been inserted in both orientations, such that CAT transcription is initiated by the vRNA promoter in one construct (pH2960), and by the cRNA promoter in the other (pH2989, Fig. 19), and vice versa for GFP expression from both ambisense constructs. In addition, also the CAT gene only has been inserted in either orientation between the 5' and 3' elements of that ambisense promoter, with CAT transcribed by the vRNA promoter in one case (pH2959), and by the cRNA promoter in the other (pH2957). The whole set of constructs allows for a direct comparison with corresponding reference constructs carrying a regular vRNA promoter (pH1844) or cRNA promoter structure (pH2583), i.e. carrying only the 5'-adjacent U₆ sequence element and no 3'-A₆ counterpart. The two groups of constructs also differ in insert size, since a single inserted gene roughly accounts for 750 nucleotides, the convergent set of two genes for 1500 nucleotides, with the distal half
40 of both mRNAs in this case remaining untranslated, a situation unusual for influenza viral mRNAs.

[0034] As is demonstrated in Fig. 10B for CAT expression of the various ambisense constructs all of them are able to initiate transcription in both orientations, even if at different levels with regard to their vRNA and cRNA promoter-dependent expressions, and also with regard to the insert lengths and convergent arrangements of the GFP/CAT versus CAT-only constructs. Analysis of the GFP expression rates (not shown) yields complementary results, i.e. again vRNA promoter-controlled GFP expression is superior over cRNA promoter expression of GFP. Therefore, individual ambisense clones either show an asymmetric high expression of GFP and low expression of CAT (pH2960) or vice versa (pH2989), depending on their orientation of reading frames with regard to the external vRNA and cRNA promoter. Fig. 10C also demonstrates successful propagation of recombinant viruses containing ambisense RNA molecules, which proves survival through amplification, packaging into virions, and expression of both mRNAs in infected MDCK cells (including besides CAT also GFP expression).

[0035] B.3. Construction of a superior promoter-up mutation, pH1920, to be used for improved rates of cRNA promoter expression in ambisense constructs:

An extended analysis of promoter variants, in particular of complementary double exchanges according to the 'corkscrew' model yielded among others variant pH1920 (Fig. 20) with CAT activity rates considerably above (125-130% of) the rates observed for standard promoter-up variant '1104' (as present in pH1844). The '1920' promoter-up variant consists of altogether 5 nucleotide substitutions relative to the wildtype promoter sequence, both in the 5' promoter element (2), and the 3' promoter element (3). The structure of this variant and the whole set of complementary double exchanges is presented in Fig. 11, together with the respective CAT activity measurements, in vRNA promoter con-

strucs. vRNA promoter-up variants also show similarly improved expression in (ambisense) cRNA constructs, even if at generally lower levels than in vRNA constructs. cRNA promoter-up expression is observed at levels similar or somewhat (2x-5x) above the *wild-type* vRNA promoter rate, while vRNA promoter-up constructs show CAT expression rates increased up to 20 or 25 times the wild-type vRNA promoter level. In either case expression rates also depend on the size of the insert, with promoter activity rates decreasing with increasing lengths of the influenza RNA molecules to be transcribed.

[0036] B.4. Influenza recombinant viruses containing a foreign gene (CAT) in covalent ambisense linkage with one of the viral genes (HA, NS1/NS2):

The principle solution in designing stable recombinant viruses based on the new properties observed for influenza transcription and replication signals consists in constructing viruses which contain a foreign gene in covalent linkage with one of the (indispensable) viral genes, in ambisense bicistronic organization. Preferably the viral gene is connected to the cRNA promoter, while vRNA promoter expression is used for expression of the foreign gene at rates considerably above the viral mRNA synthesis. The promoter-up variant chosen for constructing the ambisense RNA segment intends to bring its cRNA promoter expression (approximately) into balance with all other viral gene expression levels, which are controlled by wild-type vRNA promoters located at the termini of the seven ordinary influenza segments; the respective choice has to take into consideration the overall length of the ambisense segment.

[0037] Isolation of the ambisense recombinant virus employs an RNA polymerase I-transcribed ambisense cDNA construct, which will give rise *in vivo* to ambisense cRNA-type molecules, see Fig. 12. The plasmid DNA transfection mixture used in this step with 293T cells in addition may or may not contain four 'booster' plasmids which under pCMV control produce the four early influenza proteins from non-viral mRNAs: NP, plus PB1, PB2, and PA, i.e. the three subunits of viral polymerase (Pleschka et al., A plasmid-based reverse genetics system for influenza A virus J. Virol. 70, 4188-4192 (1996)), which will increase in a pre-amplification step the copy number of that ambisense viral cRNA segment. At 18 h post transfection the 293T cells are infected by a ribozyme-sensitive influenza strain, e.g. vHM41, which will supply (again) early and also late viral RNAs. The resulting supernatant which contains a mixture of vHM41 carrier virus and vHM41-derived ambisense recombinant virus (nine vRNA segments) is then passaged directly or via an intermediate step of amplification on MDCK cells onto 293T cells that have in advance been DNA-transfected by ribozyme-producing pAM424. Here, the ribozyme-sensitive vRNA segment of vHM41 will be cleaved at its 2x2 target sites by pAM424 specific ribozymes. In recombinant viruses the vRNA gene lost in this way is re-supplemented through its presence within the ambisense segment. The virus-containing supernatant is passaged for amplification and further purification through ribozyme treatment a second time on 293T cells which again have been pretreated by pAM424 DNA transfection.

[0038] Absence of ribozyme-sensitive vRNA, and presence only of ambisense RNA in RT-PCR analysis at this stage allows for further amplification on MDCK cells and a final virus stock preparation on embryonated chicken eggs. CAT assays can be used to analyse for the presence and monitor the activity of this model foreign gene through the various steps of isolation and propagation as well as document technical improvements that might be worked out for one or more of the processive stages.

C. Examples for application of helper-free, stable recombinant influenza viruses

[0039] C.1. Incorporation of reporter gene GFP in NS/GFP or HA/GFP ambisense segments:

Recombinant viruses of this type will allow to follow-up on influenza infection instantly and continuously in individual infected cells, which may also be counted or documented by fluorescence photography or FACS sorting. With improved temperature resistance (Siemering et al., Mutations that suppress the thermosensitivity of green fluorescent protein. Curr. Biol. 6, 1653-1663 (1993)) GFP expression becomes visible at 2 h after infection and shows bright fluorescence after 4 h p.i., it will be possible to follow-up on the spread of viral infection by GFP fluorescence. Stable fluorescence in abortively infected cells e. g. observed in *ex vivo* treatment of dendritic cells similarly supports a follow-up on their reincorporation into animals; other genes may be incorporated by ambisense vRNA into dendritic cells in the same way.

[0040] C.2. Construction of glycoprotein CSFV-E2 carrying influenza, helper-free:

The glycoprotein E2 of CSF virus has been incorporated previously into influenza both as an HA-anchor fusion protein within the viral envelope, and as an additional, unstable ninth vRNA segment into its genome (Zhou et al.; Membrane-anchored incorporation of a foreign protein in recombinant influenza virions. Virology, 246, 83-94 (1998)). Stabilization is now achieved through an ambisense connection with either of the regular viral RNA segments (NS or HA) which also allowed to reach a level of 100% recombinant viruses instead of an hitherto only 20% (Fig. 13), since all carrier viruses are destroyed through ribozyme action, see Figs. 8 and 12. The helper virus containing preparation has already been used successfully as a vaccine against CSFV infection (antibody titers of 1:40000); the increase achieved in recombinant viruses allows a further improvement in that regard. Also (cost-effective) propagation in fertilized chicken eggs has become possible due to its stable incorporation of the foreign gene as a covalent ambisense construct.

[0041] C.3. Construction of hepatitis C glycoprotein-carrying recombinant influenza viruses as a candidate vaccine:

Hepatitis C virus is a close relative of CSF virus (hog cholera virus), and in particular its set of two glycoproteins, small-size E1 and larger-size E2, is closely related in structural detail and presumably also in function to the corresponding CSFV proteins. An incorporation of HCV-E2/HA fusion proteins into influenza viral envelopes has been achieved in analogy to the CSFV-E2/HA incorporation. In addition, incorporation of an anchor-fusion glycoprotein HCV-E1/HA or both together (in NS and HA ambisense junctions) allows further variations in constructing an influenza-based vaccine for hepatitis C. In analogy to CSFV-E2, neutralizing antibodies are expected to be directed against particular epitopes of HCV-E2, presented in essentially native conformation at the influenza viral envelope.

[0042] C.4. Stable incorporation of selected influenza T-cell epitopes in ambisense constructions:

Influenza infection is known to result in both, antibody production against that specific viral strain or indeed its epitopes that are located mainly at the surface of HA, and in an increase of specifically primed cytotoxic T-lymphocytes, stimulated by T-cell epitopes primarily located within the essentially invariable core structure of the NP protein. While the humoral response will result in life-long immunity against *that particular* strain of influenza or its epitope structures, the T-cell response will be lost or severely reduced some time afterwards, such that its specificity against influenza in general will fall below protective levels. One way in trying to increase that level of cellular immunity is to enhance the response or recruitment of influenza-specific CTL cells by increasing the level of T-cell epitopes in the infected cell and hence its presentation on the surface by MHC-I receptors. This is achieved by combining in an ambisense construct the HA gene and a series of repeated T-cell epitope sequences as present in the influenza NP gene, in a model design specific for the BALB/C mouse MHC-I allele. Here, the promoter-up expression rate is realized (in vRNA promoter-controlled initiation) for expression of the repetitive epitope polypeptide chain. Alternatively or in addition a controlled secretion of an interleukin can be achieved from recombinant influenza-infected cells, upon ambisense incorporation of the respective gene preferably into the NS segment. The interleukin to be chosen for this purpose (IL-12 or other) is selected to enhance the longevity of influenza-specific CTL cells or its conversion into corresponding memory cells. In this way an ambisense vaccine strain against influenza itself is achieved with expected protective capacity against influenza in general.

[0043] C.5. Exchange of influenza glycoproteins against foreign viral glycoproteins (VSV-G):

The 'marker rescue' experiment described above (section A.4.), i.e. an exchange of one HA gene (ribozyme-sensitive) for another (ribozyme-resistant) can also be used for an exchange of HA for an entirely different glycoprotein, such as the vesicular stomatitis virus G protein, as long as it is attached to the HA anchor segment. Effective incorporation depends always on that C-terminal tail sequence and its interaction with underlying matrix protein M1, and therefore, all constructions consist of fusion proteins in direct analogy to CSFV-E2. VSV-G with or without a foreign anchor sequence has been shown in several other viruses to be able to substitute for the original glycoprotein and to result in infectious viruses with VSV-G specific host-ranges (e.g. in retroviruses, rabies virus, measles virus). G protein in VSV itself as well as on the surface of foreign viruses is the only glycoprotein required for all of the consecutive steps in infection. Insertion of VSV-G instead of HA in recombinant influenza viruses leaves the second glycoprotein, neuraminidase, without any function, which then will get lost spontaneously from the recombinant viruses. This will further increase the capacity for an addition of foreign genes, beyond the gain resulting from an exchange of the larger HA for the smaller VSV-G, which might be used for an addition of ambisense constructs.

[0044] The invention is further illustrated in the accompanying figures.

40 Description of the figures

[0045]

Fig.1. 3' nucleotide extensions of influenza vRNA template molecules:

(A) Murine B82 cells have been transfected by plasmid cDNA constructs designed to be transcribed into influenza vRNA molecules by RNA polymerase I *in vivo*, followed after 20 h by standard FPV_{Bratislava} helper virus infection, at an moi of 1 to 3. In addition to reference plasmid pH2024 (no extension), related cDNA constructs carrying extensions of 1 to 50 bp, and hence extended by 1 to 50 nucleotides at the resulting vRNA 3' ends were used in parallel transfections; template extensions are marked at the top of the figure. Cell lysates prepared at 8 h post helper virus infections were used for CAT reactions using in one round 50 µl of cell lysate each, and in further analyses 5 µl and 0.5 µl of lysate (not shown). Relative yields were determined in comparison to reference plasmid pH2024, as indicated below the figure, with calculations restricted to those CAT assays showing less than 40% of substrate consumption, in three or more independent experiments.

(B) Viral passage of B82 supernatants containing recombinant influenza virus onto MDCK cells, at an moi of 2 to 4, in average. Again at 8 h post infection cell lysates have been prepared and used for CAT assays. Relative yields as indicated below the figure have been determined in comparison to pH2024 the same way

as in (A), using 0.5 µl of cell lysate in each case. (The 50 µl CAT assays as shown here and also in the following figures intend to give an immediate impression of relative activities at always the same level, while the actual measurement data as indicated below the lanes are obtained at various appropriate enzyme concentrations relative to reference pH2024.)

5

Fig. 2. Propagation of recombinant influenza viruses with tandem bicistronic vRNA:

(A) General design of expression plasmids for transient bicistronic vRNAs coding for GFP in the mRNA-proximal, and for CAT in the mRNA-distal position. Among the functional elements indicated are the human RNA polymerase I promoter (p_{lh}) and murine rDNA terminator (t_l) sequences, both hatched, and the 5' and 3' vRNA promoter cDNA sequences, open and closed boxes, respectively. For the vRNA-internal 3' promoter signal three variant sequences have been inserted as indicated below (positions 1 to 15 refer to 3'-terminal nucleotides in the resulting monocistronic vRNAs).

10

(B) CAT assays as determined relative to pH1844 (monocistronic CAT construct) after DNA transfection of 293T cells plus helper virus infection followed by one round of progeny viral propagation on MDCK cells are indicated *below* the lanes. Relative activities of the internal promoter sequences as indicated *above* the figure refer to measurements in a monocistronic *external*/location of the same promoter variants (Flick *et al.*, Promoter elements in the influenza vRNA terminal structure, RNA 2, 1046-1057 (1996)). Control clone pH2300 contains an unrelated, non-functional sequence in the central location in an otherwise identical plasmid construct.

15

20

Fig. 3. Tandem bicistronic vRNA supporting an alternative mode of transcription and replication initiation:

An additional internal 3' promoter sequence has been inserted in between both cistrons, in a vRNA-central position. Left half: bicistronic replication and transcription leading to (proximal) GFP expression. Right half: internal initiation resulting in monocistronic replication and transcription leading to (distal) CAT expression, and causing deletion of the GFP sequence from progeny molecules.

25

Fig. 4. Outgrowth of promoter-up recombinant vRNA versus wildtype vRNA segments in stepwise propagation of influenza virus:

RNA polymerase I transcription of transfected pH2969 DNA results in influenza vRNA carrying (an external) promoter-up mutant '1104', and containing 2x2 ribozyme targets in flanking positions relative to its HA coding sequence. Another HA vRNA segment in wild-type configuration and originating from infecting FPV helper virus is also present in the recombinant virus preparation, initially (lane 1; 293T lysate) in surplus amounts, but reduced and finally lost entirely in consecutive steps of propagation (lanes 2 to 4; MDCK cell lysates), and in isolated strains after pAM403 ribozyme treatment for removal of the external '1104' promoter sequence (lane 5). Determination throughout by RT-PCR analyses using a pair of primers extending across the 5' inserted target site sequence, with 435 bp representing the recombinant HA segment, and 306 bp the wild-type sequence without an inserted target site sequence.

30

35

40

Fig. 5. pAM403 ribozyme cleavage of pH2969 derived vRNA molecules at specific target sites inserted between an external and an internal 3' promoter sequence:

The external promoter-up ('1104') signal is used for vRNA amplification within recombinant viruses and reduction of helper virus HA vRNA (Fig. 4), while the 'switch' to an internal wild-type signal guarantees stable replication of recombinant viruses. pAM403 hammerhead ribozyme RNAs are indicated in complementary binding to their target site sequences (12 and 10 nucleotides flanking the GU'C cleavage point) by straight lines flanking a central secondary structure symbol. vRNA-internal 2x2 ribozyme targets are marked by xx (see Fig. 7).

45

Fig. 6. Comparative cleavage analysis of model CAT vRNAs with tandem target sites in various flanking positions, by target-specific ribozymes:

293T tissue culture cells have been transiently DNA-transfected either by a single-headed hammerhead ribozyme (s), or a double-headed (d), or triple-headed (t) ribozyme cDNA construct, all specifically designed to hybridize to a tandem dimer target site sequence inserted in flanking positions into the CAT vRNA. All ribozyme RNAs have been expressed from the same pSV2-neo plasmid vector, including a pSV2-neo control construct without an inserted ribozyme cDNA sequence (c). At 20 h after DNA transfection (which reached 65% yield as measured by PCMV-GFP transfection in parallel of the same cell culture) the 293T cells were infected by CAT recombinant viruses carrying tandem double target sequences either only in vRNA-3' position, or in both vRNA-3' and 5' positions, or in both vRNA-3' and cRNA-3' positions. Most effective among the s, d, or t-ribozymes were double-headed constructs, acting on 2x2 targets inserted in either of the two localizations described (lanes 6 and 10).

55

Fig. 7. Alignment of pAM424 double-headed ribozyme with one of their repetitive target sequences located within the 5' and 3' vRNA flanking regions:

The superior activity of ribozymes oriented against targets located in the 3' end of vRNA molecules over those present in the 5' end instead (not shown) is in agreement with the model for influenza vRNA transcription and replication (Lamb and Krug, Orthomyxoviridae: The viruses and their replication. In 'Virology' (B.N.Fields, D.M. Knipe, P.M.Howley, R.M.Chanock, J.L.Melnick, T.P.Monath, B.Roizman, and S.E.Straus, Eds.), 3rd ed., Vol. 1, pp. 1353-1395. Lippincott-Raven, Philadelphia (1996)), according to which influenza polymerase stays attached to the 5' end of the vRNA molecule throughout the entire or even several rounds of transcription, whereas the very 10 3' end repeatedly, in every initiation reaction serves as the template sequence, and consequently is no longer covered by polymerase. Superiority of a double-headed over a single-headed ribozyme has been determined earlier in this laboratory (A.Menke, Anti-Influenza Ribozyme: vRNA-Spaltung und intrazelluläre Aktivität. Dissertation Universität Giessen (1997)), but the substantial increase of vRNA inactivation rates upon incorporation of tandem target sites at both ends of the vRNA molecule instead of only one has been observed here for the first time, within that overall design.

Fig. 8: pAM424 ribozyme cleavage of resistant FPV wild-type HA vRNA and ribozyme-sensitive pHL2969-derived HA-vRNA in 293T cells infected by vHM41 after isolation from pHL2969-recombinant viral preparations. Lane 1: FPV infection of 293T cells, untreated; lane 2: FPV infection of 293T cells DNA-transfected by pAM424; lane 3: vHM41 infection of 293T cells, untreated; lane 4: vHM41 infection of 293T cells DNA-transfected by pAM424. RT-PCR analyses of purified viral progeny as in Fig. 4.

Fig. 9 Functional analysis of the influenza cRNA promoter structure:

- (A) Schematic cRNA promoter ('1104') secondary structure according to the 'corkscrew' model; nucleotides involved in single or double nucleotide exchange are marked by their position.
- (B) CAT analyses of 293T cell lysates after DNA transfection and FPV helper virus infection of cRNA promoter variants, in comparison to standard vRNA promoter-up mutant '1104' (pHL1844). Nucleotide substitutions divergent from the basic '1104' structure as present in pHl2583 or pHl2721 (see above) are indicated above the lanes, positions 3 or 8 as marked by a bar refer to cRNA positions counted from the 3' end. Relative CAT activities are marked below the lanes.

Fig. 10 Functional analysis of the vRNA and cRNA promoter in ambisense arrangement:

- (A) Sequence organisation of the ambisense promoter cDNA construct carrying T₆/A₆ elements adjacent to the terminal sequence, and secondary structure predictions for the resulting cRNA and vRNA promoter signal.
- (B) CAT expression data obtained from the cell lysates of 293T cell after plasmid DNA transfection and FPV infection, and (C) from cell lysates of MDCK cells after one step of viral passage. Indicated above the lanes are promoter/gene conjuncions: v = vRNA promoter; c = cRNA promoter.

Fig. 11 Basepair substitutions according to the vRNA 'corkscrew' structure:

- (A) 'Corkscrew' conformation of the vRNA promoter drawn against a schematic indication of interacting tripartite viral polymerase. Paired positions exchanged in individual experiments are indicated by numbers, nucleotides 3 or 8 are counted from the 3' end. pHl2024 containing promoter-up mutation '1104' is used as the reference construct (=100%) in all of the CAT assays, while pHl2428 represents the wild-type promoter structure.
- (B) CAT expression data obtained after one step of viral passage in MDCK undiluted, and 50 fold diluted.

Fig. 12: Flow-chart of the isolation procedure for an ambisense recombinant influenza virus.

Fig. 13 Immuno-electron microscopy of purified influenza FPV/CSFV-E2-HA virions: Recombinant viruses exposing the foreign glycoprotein CSFV-E2 in their envelopes, which has been fused onto the HA anchor domain, are marked by anti-E2 monospecific antibody and by secondary gold-labelled (5nm) goat antibody. Recombinant viruses (16%) are present together with their FPV helper viruses.

Fig. 14: pHl2969; the exact sequence of the 4930 bps circular DNA is shown in SEQ.ID NO:1.

Fig. 15: pAM403; the exact sequence of the 5811 bps circular DNA is shown in SEQ. ID NO:2.

Fig. 16: pAM424; the exact sequence of the 5860 bps circular DNA is shown in SEQ. ID NO:5.

Fig. 17: pHl2507; the exact sequence of the 4610 bps circular DNA is shown in SEQ. ID NO:6.

5 Fig. 18: pHl2583; the exact sequence of the 3558 bps circular DNA is shown in SEQ. ID NO:7.

Fig. 19: pHl2989; the exact sequence of the 4343 bps circular DNA is shown in SEQ. ID NO:8.

10 Fig. 20: pHl1920; the exact sequence of the 3888 bps circular DNA is shown in SEQ. ID NO:9.

[0046] Hence, the present invention is based on two surprising findings, namely

1. influenza virus promoters are active when present internally in a gene;
2. the so-called cRNA, thought to be an intermediate in replication can be turned into a protein-encoding RNA by equipping it with a variant influenza virus promoter, described in the present invention.

[0047] These two observations were used to make ambisense constructs. This allows to package an additional, foreign gene into influenza virus particles. Such particles were made previously, by other methods, but proved to be unstable, and therefore useless. For use as a vaccine for example, a helper virus would have been needed as a stabilizer. Stabilization in the present invention is achieved by several means. These include the "balancing" of one of the two promoters in the ambisense bicistronic genetic construct with seven other vRNA wildtype promoters, while the additional promoter is used for high-rate expression of the foreign gene at various levels.

[0048] Thus, the present invention provides a system for expression of foreign proteins in higher eukaryotic systems. One system in particular is interesting, namely embryonated chicken eggs, as it allows cost-effective production in an automatable way (as used by most flu vaccine producers). The reason that this process is now possible, is that the foreign protein is part of a stable, engineered influenza virus particle. The virus can be designed also to rapidly monitor process improvements.

[0049] An excellent use is of course the use of the construct as a vaccine. The influenza virus particle is immunogenic and can now be equipped with foreign antigens, enabling for example the design and production of hepatitis C virus and HIV vaccines, but also of tumor vaccines. As the present invention shows, the foreign antigenic surface glycoprotein is "fused" to a C-terminal segment of influenza HA, and the antigen then is presented at the surface of influenza virus particles. In addition, these vaccines can now be made in the way standard flu vaccines are made, i.e., in embryonated chicken eggs.

35

40

45

50

55

SEQUENCE LISTING

<110> ARTEMIS PHARMACEUTICALS GmbH
 5 <120> Stable Recombinant Influenza Viruses Free of Helper
 Viruses
 <130> 990383ep
 10 <140>
 <141>
 <160> 9
 15 <170> PatentIn Ver. 2.1
 <210> 1
 <211> 4930
 20 <212> DNA
 <213> Influenza virus
 <400> 1
 cgtacgaagc ttcttagaggg attggctgag acgaaaaaca tatgcttagag ggattggctg 60
 agacgaaaaa catatgctag agccggccgc accgcggtgg agctccagct tttgttcct 120
 25 ttagtgaggg ttaattgcgc gcaggcctag cttagttaag aaaaataccc ttgtttctac 180
 taataaccccg gccccccaaa atgcgcactc ggagcggaaag atataacctcc cccggggccg 240
 ggaggtcgcg tcaccgcacca cgccgcggc ccaggcgacg cgcgcacacgg acacctgtcc 300
 ccaaaaacgc caccatgcacca gccacacacgg gagcggccgg ggccctctgg tcaaccccg 360
 gacacacgcg ggagcagcgc cggccgggg acgcctccc ggccgcccgt gccacacgca 420
 ggggggccgc ccgtgtctcc agagcggggag cgggaagcat ttccggccgg cccctctac 480
 gaccgggaca cacgagggac cgaaggccgg ccaggcgacg cctctcgggc cgcacgcgc 540
 ctcaggggagc gctctccgac tccgcacggg gactcgccag aaaggatcgat gacctgcatt 600
 aatgaatcag gggataacgc aggaaagaac atgtgagcaa aaggccagca aaaggccagg 660
 aaccgtaaaa aggccgcgtt gctggcgtt ttccataggc tccgggggg tgacgagcat 720
 30 cacaaaaaatc gacgtcaag tcagagggtgg cgaaaaaccga caggactata aagataccag 780
 gcgtttcccc ctggaagctc cctcgtgcgc tctctgttc cgaccctgcc gcttaccgg 840
 tacctgtccg ccttctccc ttccggaaagc gtggcgctt ctcatacgctc acgctgttagg 900
 tatctcagtt cggtgttaggt cgttcgctcc aagctggct gtgtgcacga acccccccgtt 960
 35 cagcccgacc gctgcgcctt atccggtaac tategtctt agtccaaccc ggtaaagacac 1020
 gacttatacgc cactggcagc agccactggt aacaggattt gcagagcgcgat gtatgttagc 1080
 ggtgctacag agttttgaa gtggggcct aactacggct acactagaag gacagtattt 1140
 ggtatctgcg ctctgctgaa gccagttacc ttccggaaaaa gagttggtag ctcttgatcc 1200
 ggcaaaacaaa ccaccgctgg tagcggtgg tttttgttt gcaaggcagca gattacgcgc 1260
 agaaaaaaaaa gatctcaaga agatcctttagt atctttcta cggggctctga cgctcagtgg 1320
 40 aacgaaaact cacgttaagg gatttggtc atgagattat caaaaaggat cttcacctag 1380
 atccttttaa attaaaaatg aagttttaaa tcaatctaaa gtatatatga gtaaacttgg 1440
 tctgacagtt accaatgctt aatcagttagt gcacccatct cagcgatctg tctatttcgt 1500
 tcatccatag ttgcctgact ccccgctgtg tagataacta cgatacgggg gggcttacca 1560
 45 tctggcccca gtgcgtcaat gataccgcga gacccacgct caccggctcc agatttatca 1620
 gcaataaaacc agccagccgg aaggggccgag cgcagaagtg gtcctgcacac tttatccgccc 1680
 tccatccagt ctattaattt ttgcggggaa gctagatggaa gtagttcgcc agttaatagt 1740
 ttgcgcacacg ttgttgcctt tgctacaggc atcgtgggtgt cacgcgtcgcc gtttggatg 1800
 gcttcattca gctccgggttc ccaacgatca aggcgagttt catgatcccc catgttgc 1860
 aaaaaaaggcg tttagtctttt cgggtctccg atcgttgtca gaagtaagt ggcgcagtg 1920
 50 ttatcactca tggttatggc agcaactgcat aattcttta ctgtcatgcc atccgtaaaga 1980

<210> 2
<211> 5811

<212> DNA

<213> Inf]

55 <213> Influenza virus

<400> 2
 5 aattccttgc ccaaaaaactt aacctgtgga aatattttga tgtggaaagc 60
 tgtaactgtt aaaactgagg ttattggggt aactgctatg ttaaacttgc attcaggac 120
 acaaaaaactt catgaaaatg gtgctggaaa acccattcaa ggtcaaaatt ttcattttt 180
 tgctgttgtt gggaaacctt tggagctgca ggggtgtta gcaaactaca ggaccaata 240
 tcctgtccaa actgtAACCC caaaaaatgc tacagttgac agtcagcaga tgaacactga 300
 ccacaaggct gtttggata aggataatgc ttatccatgt gagtgtctggg ttcctgatcc 360
 aagtaaaaat gaaaacacta gatattttgg aacctacaca ggtggggaaa atgtgcctcc 420
 10 tttttgcac attactaaca cagcaaccac agtgcctt gatgagcagg gtgttggcc 480
 ctgtgcaaa gctgacagct tttatgtttc tgctgttgac atttgtggc tttttaccaa 540
 cacttctgga acacagcagt ggaagggact tcccagat tttaaaattt cccttagaaa 600
 gcggtctgtt aaaaacccctt acccaatttcc tttttgtt agtgcaccaa ttaacaggag 660
 15 gacacagagg gtggatgggc agccttatgtat tggaaatgtcc tctcaagtag aggaggttag 720
 gttttatgag gacacagagg agcttctgtt ggatccagac atgataagat acattgtatg 780
 gtttggacaa accacaacta gaatgcagt aaaaaaatgc ttttttggaa aatatttgc 840
 tgctattgtt ttattttgtt ccattataag ctgcaataaa caagtttaca acaacaattt 900
 cattcattttt atgttctagg ttcagggggg ggtgtgggat gttttttaaa gcaagttaaa 960
 20 cctctacaaa tttgttatgg ctgattatg tctctagtca aggcactata catcaaataat 1020
 tccttattaa cccctttaca attaaaaatggtca acaatttttgc agcatagtttta 1080
 ttaatagcag acactctatg cttgtgttgc gtaagaaaaa acagtatgtt atgattataa 1140
 ctgttatgcc tacttataaa gtttacagaa ttttttcca taatttttctt gtatagcagt 1200
 25 gcagctttt ctttgggtt gtaaatagca aagcaagcaa gagtttctt actaaacaca 1260
 gcatgactca aaaaacttag caattctgaa ggaaagtctt tgggttctt taccttctc 1320
 ttctttttt gaggagtaga atgttgcagg tcaagcactt cctcatcattt actagatggc 1380
 atttttttcg agcaaaacag gttttctca ttaaaggcat tccaccatg ctccccattca 1440
 tcagttccat agyllgyaa claaaataca caaacaattttaa gaatcgttagt ttttacacat 1500
 tatacactta aaaaatttttattttaa gagctttttt tttttttttt tagtttgc 1560
 30 aattatgtca caccacagaa gtaagggttcc ttcacaaaga tccgggacca aagcggccat 1620
 cgtgcctccc cacttctgca gttcgggggc atggatgcgc ggatagccgc tgctgggttc 1680
 ctggatggcc acggatttgc actgcccggta gaactccgcg aggtcgttca gcctcaggca 1740
 gcagctgaac caactcgccgaa ggggatcgag cccgggggtgg gcaagaaactt ccagcatgag 1800
 atccccggc tggaggatca tccagccggc gtccggaaa acgatccgcg agcccaaccc 1860
 35 ttcatagaag gccccgggtgg aatcgaaatc tttgtatggc agtttgggcg tgctttggc 1920
 ggtcatttcg atgaatttgc gtcgttacc cggggatctt cttagggcat ttcagtttcg 1980
 tcctcacgga ctcatcagag ttgctcaattt cgaaccccg agtcccgctc agaagaactc 2040
 gtcaagaagg cgatagaagg cgatgcgtt cgaatccggc gccccggatccgatc cgtaaagcac 2100
 gaggaagcgg tcagccccattt cggcccaag ctcttcagca atatcacggg tagccaaacgc 2160
 tatgtcttgc tagccgtccg ccacaccccg cccggccacag ttcgttgcgatc cagaaaagcg 2220
 40 gcccatttcc accatgat ttcggcaagca ggcattccca tgggttccatc cggatccctc 2280
 gccgtcgccgatc atgcgcctt tgacgttgcgaa acgatccgcg gtttttttttgcgatc 2340
 ctcttcgtcc agatcatttgc gatcgacaaacccgcgttccatc atccgatgttgc ttttttttttgc 2400
 gatgcgtatgtt ttcgttgtt ggtcaatggtgcgatgttgcg ggtcaagcg tatgcagccg 2460
 45 ccgcatttgc tcaagccatgc tggatactttt ctcggcaggaa gcaaggttgcgatgttgc 2520
 atccctggccccc ggcacttcgc ccaatagcag ccagttccctt cccgttccatc tgacaaacgc 2580
 gagcacaatgc ggcacaggaa cggccgtcgatgttgcg gggccatc gatagccgcg ctgcctcg 2640
 ctgcagttca ttcagggttgc cggacaggatgttgc ggttccatgtt ggtcaatggtgcg ggtcaagcg 2700
 cgttgcacgc cggacacacgg cggcatcaga gcaagccgtt gtttttttttgcgatgttgc 2760
 gcccggatccgc ctctccaccc aagccggccgg agaaccttgcg ttcgttgcgatgttgc 2820
 50 catgcgaaac gatccctatc ctgttcttgc atcagatctt gatcccttgc gccatcagat 2880
 ctttggccgc aagaaagcca tccagtttac ttttttttttgcgatgttgc 2940
 cggcccccagct ggcaattccg gtttgcgttgc ttttttttttgcgatgttgc 3000
 ccatgttgcacgc ccacttgcag ctacccgtt ttttttttgcg ttttttttttgcgatgttgc 3060
 gatagcccgatgttgc ttttttttttgcgatgttgc 3120
 55 ctttttttttgcgatgttgc 3180

ttgcaaaagc ctaggcctcc aaaaaagcct cctcaactact tctggaaatag ctcagaggcc 3240
 gagggcgccct cgccctctgc ataaaataaaa aaaatttagtc agccatgggg cgagaaatgg 3300
 gcggaactgg gcggagttag gggcgggatg ggcggagttt gggggcyggac latgggtgct 3360
 5 gactaattga gatgcatactt ttgcatactt ctgcctgtg gggagccgtgg ggactttcca 3420
 cacctggttt ctgactaattt gagatgcatg ctttgatactt ttctgcctgc tggggagccct 3480
 ggggactttc cacaccctaa ctgacacaca ttccacagct gctcgccg tttcggtgat 3540
 10 gacggtgaaa acctctgaca catgcagctc ccggagacgg tcaacagctt tctgttaagcg 3600
 gatgccggga gcagacaagc ccgtcaggc gcgtcagcgg gtgttggcgg gtgtcgggg 3660
 gcagccatga cccagtcaacg tagcatacg ggagtttata ctggcttaac tatggggcat 3720
 cagagcagat tgtaactgaga gtgcacccata tgccgtgtga aataccgcac agatgcgtaa 3780
 ggagaaaata cccatcagg cgcttcccg ttccctcgct cactgactcg ctgcgtcgg 3840
 tcgttcggct gcggcgagcg gtatcagctc actcaaaggc ggtataacagg ttatccacag 3900
 aatcagggga taacgcagga aagaacatgt gggaaaagg ccagccaaag gccaggaaacc 3960
 15 gtaaaaaggc cgcgttgcgt gctttttcc ataggctccg ccccccgtac gacatcaca 4020
 aaaatcgaacg ctcaagtcaacg aggtggcgaa acccgacagg actataaaaga taccaggcgt 4080
 ttccccctgg aagctccctc gtgcgtctc ctgttccgac cctggccctt accggataacc 4140
 tgcgtgcctt tctccctcg ggaagcgtgg cgcttctca tagctcacgc tgggtgtatc 4200
 tcagttcggt gtaggtcggt cgctccaagc tgggtgtgt gcacgaaccc cccgttcagc 4260
 20 cccgaccgtg cgccttatcc ggttaactatac gtcttgagtc caacccggta agacacgact 4320
 tatacgccact ggcagcagcc actggtaaca ggatttagcag agcggatgtat gtagggcgtg 4380
 ctacagagtt ttgttaactt acggctacac tagaaggaca gtattttgtt 4440
 tctgcgtct tctgtttttt gaaaaagagt tggtagctt tgcgttcggca 4500
 aacaaaccac cgctggtagc ggtgggtttt ttgtttgcaaa gcagcagatt acgcgcagaa 4560
 25 aaaaaggatc tcaagaagat cctttgatct ttcttacggg gtctgacgt cagtggaaacg 4620
 aaaactcacc ttaagggatt ttgttcatga gattatcaaa aaggatcttc acctagatcc 4680
 ttttaattt aaaaatgaagt tttaaatcaa tctaaatgtt atatgagttt aacttggctcg 4740
 acagttacca atgccttaatc agtgaggcac ctatctcagc gatctgtcta ttctgttcat 4800
 ccatagttgc ctgactcccc gtcgtgtaga taactacgtt acggggaggcgtt ttaccatctg 4860
 30 gccccagtgc tgcaatgata ccgcgcgacc cacgttcacc ggctcccgat ttatcagcaa 4920
 taaaccagcc agccggaaagg gcccgcgcgca gaagtggtcc tgcaacttta tccgcctcca 4980
 tccagtttat taattttgtgc cgggaagctt gagaatgtt ttcgccttgcgtt aatagtttgc 5040
 gcaacgttgt tgccattgtt gcaggcatcg tgggtgtacgc ctgcgtcggtt ggtatggctt 5100
 cattcagtc cgggtcccaa cgatcaaggc gaggatcatg atccccatg ttgtcaaaa 5160
 35 aaggcggttag ctccctcggtt cctccgatcg ttgtcagaag taagttggcc gcagtttat 5220
 cactcatgtt tatggcagca ctgcataattt ctcttactgtt catggccatcc gtaagatgt 5280
 ttctgtgttgc ttgttgcgtt tcaaccaatgtt cattttgttgc gatgttgcacgc 5340
 gttgttgcgtt cccggcgtca acacgggata ataccgcgc acatagcaga actttaaaag 5400
 tgctcatcat tggaaaacgt ttttcggggc gaaaacttcc aaggatctt ccgcgttgc 5460
 40 gatccagttc gatgttaccc actcggtgcac ccaactgttgc ttctgttgc tttactttca 5520
 ccagcggttcc tgggttgc gggatgttgc aaaaacaggaa ggcaaaatgc cgcaaaaaag ggaataagg 5580
 cgacacggaa atgttgcata ctcataactt ttcgttttca atattattgtt agcattttatc 5640
 agggtttttgc ttcatgttgc ggatacatat ttgttgcgtt ttagaaaaat aaacaaatag 5700
 gggttccgcg cacatttccc cggaaatgttgc cacctgtacgtt ctaagaaaacc attattatca 5760
 tgacatcaaacttataaaaaat aggcttatca cgaggccctt tcgttccaaat 5811
 45
 <210> 3
 <211> 2005
 <212> DNA
 <213> Influenza virus
 50
 <400> 3
 agtagaaaca agggtatttt tctttaccta gctaggctt cgcgcattttt accctcaacta 60
 aaggaaacaa aagctggcgc tccaccgcgg tggggccgc tctagcatat gttttcgatc 120
 tcagccaaatc cctcttagcat atgttttgc ttcacgcacaa tccctctaga agcttcgcac 180
 55 gcatgcacatc tttaaatgcata tataatgcac cgcatgtttt cgttccatc acatatgaaa 240

5 acaaggccca ttgcaatggc aagaagcaa aagcatgtat cccccgaagct aaaccaaaagt 300
atcacatctt ttagccact actcaatttg actgggtcaa ttgttatcl. atttgcattc 360
gcttcttctc tgatattgct gtatcataa gtattgtcc ttatacttagc catacaatca 420
tcgtcacatt tatgaaaaat ttcaagcaa ccagtgcct cctcttcagc atttccctt 480
aattgtttcc tcactcgctc atacagcttg ttcatctctg aatcagccaa atcaatagt 540
tgctggggccat ccattgcccac aagaaggtaa gcattgtaa accataacttc tggatggag 600
tctttggtcc agttaattaa attgccaatc tgctttcca cttcagtgaa ttcatatct 660
attagctcaa attgtgtgtt ggtttttta atgagttat ttaactttcc ggttatctga 720
tcaattggccg atgggtgtt ttgttagtct getgcagttc cttcttcctt tgcattctga 780
tgcctgaaac cgtaccaccc gtcgaccaga cttccaaac catttcaat aaacctgt 840
atagcaccaa acaggccctt tttttccctt tttttggaaag gttcggaaac gttcttcate 900
ccagttgcca ataataaaact ttctgtttt acatatcttgc ggcatttgcc aactgtctg 960
ctatTTatgt ttgaaaagg caatctgtt ttatgttcc ctccactgtg gtagcattcc 1020
ccttcgcaat tagcatcaac ctgcacatcg ctctggatcc ccatggactt tccctcaag 1080
15 aagctggcac gatttggagc tatgaaagcc ccattgaaac taaaagtaac tgtatcattt 1140
ggatccaaga tcaaccaatg aaaatcaatc cgccggacc ggccatttat ctgcggcgt 1200
gttcctggac tcggcacaaa agattgtatga tatttggaaac tcccactgt tatcatttt 1260
tttccactcc catatagttt ggtctgttgc gtgttgatc ctgaatggtg gattccccag 1320
actatcagag ctgattctt ccctgtttt ttgtatgatt ttgtcatttt tgaaaagaa 1380
20 gcattgtctg tatttgcacag gagccactcc atttctgtat agaatgaaga ccctgatctt 1440
ctacatgcac tagttgtcc ttgggtctt attccactat atgtgaatcc catttttct 1500
ttgtcaatcc cacctgatec tctgaggatt tgcgcaatg cctcttcatt aacaaacttc 1560
cccgggttaac aaacatcatt tccttcgtt ctctcgatta ttagatcagc taaaattct 1620
25 agaaaatttgtt cgatttgagg tggccggta atggcccta acagtcgcata ttggccaaaga 1680
tcagtggttc tttccctt tgagcaatt ttggggatgt ttgtccgtc cactgtttcc 1740
gttgcattga caacttctac tcctctctca gtgagttgtt ttactttgtt gccatttgat 1800
acagcatgtat gtccaaagaca aattttgtct gcattttgtgg ggtatgactgc cgcaaggccg 1860
aaaaccagga ttgtgatgtt cattttggta cctacaatataat gtttttcgtc tcagccaaatc 1920
cctggtacaa tatgttttcc gtctcagccaa atcctggatc gatgtggatg tcactcagtg 1980
30 aqtqattatc taccctqctt ttgtct 2005

<210> 4
<211> 1146
<212> DNA
<213> Influenza virus

	<400> 4	
40	agtagaaaaca agggtatTTT tctttaccta gctaggcctg cgcgcaatta accctcacta 60 aaggaaacaa aagctggagc tccaccgcgg tggggcccgc tctagcatat gttttcgTC 120 tcagccaatc cctctagcat atgttttgcg tctcagccaa tccctctaga agctcgtac 180 gcatgcTTAA ataagctgaa acgagaaaGT tcttatctCT tgctccactt caagcggtAG 240 ttgttaaggcT tgcatTTATG ttatttgcTTC aaaactATTc tctgttatCT tcaatCTATG 300 tctcacTTCT TCAATTAAACC ATCTTATTTc ttcaaATTc TGACTCAATT gtttcgcca 360 ttttccgcTTT ctgctttggA gggagttggag gtccccatt ctcatTAcT gtttccaAG 420 cgaatCTCTG tatagtTTca gagactcgaa ctgtgttATC attccatTC agtccTCCGA 480 tgaggacCCC aattgcATTt ttgacatCCT catcagtATG tcctggaaAGA gaaggcaATG 540 gtgaaATTc gccgacaATT gctccCTCAT CGGTTAAAGC CCTTAATAGT atgagAGTTT 600 ccagccgatc gaaaatcaca ctgaagTTTg ctTCAGTAT gatgttCTTC cccatgatecg 660 cctggTccat tctgatgca aaggaggcCTG ccactTTCTG tttgggcatg agcatgaACC 720 agtccCTTGA catCTCTTca agagtcatgt cagTTAGTA gcgtgtAGCA ggtacAGAGG 780 caatggTcat tttaagtGCC tcATCGGATT cgtccTCCAG aatccgcTCC actatCTGCT 840 ttccaacacg agtagctgtg tcgatgtCCA gaccaAGAGT gctgcCTT cccCTCAGGG 900 acttCTGTATC tccggcgaAGT cggTcaAGGA atggggcATC acccattttT tggTCTGCAA 960 atcgTTTGCg gacatGCCAA agaaaAGAGT ctacCTGAAA gcttgacaca gtgttggAA 1020 55 ccattatggT acctacaata tggTTTCTGT ctcaGccAA ccctggTACA atatgtttt 1080	

cgtctcagcc aatccctggta cgatgtggat gtcactcagt gagtgattat ctaccctgct 1140
tttgct 1146

5 <210> 5
<211> 5860
<212> DNA
<213> Influenza virus

10 <400> 5
catcgattgg ctgactgatg agtccgtgag gacgaaacga aaaacatatt gtagagctcg 60
aattcatcga aatgacccgac caagcgacgc ccaacctgcc atcacgagat ttgcattcca 120
ccgcccgcctt ctatgaaagg ttgggcttcg gaatcgttt ccgggacgcc ggctggatga 180
tcctccagcg cggggatctc atgctggagt tcttcgccta cccccgggcgc gatccccctcg 240
cgagttggtt cagctgtgc ctgaggctgg acgacccctgc ggagttctac cggcagtgca 300
15 aatccgtcgg catccaggaa accagcagcg gctatccgcg catccatgcc cccgaactgc 360
aggagtgggg aggcacgatg gccgccttgg tcccgatct ttgtgaagga accttacttc 420
tgtggtgtga cataatttggaa caaactacct acagagattt aaagctctaa ggttaaatata 480
aaattttaa gtgtataatg tgtaaacta ctgattctaa ttgttttgtt attttagatt 540
ccaacccatag gaactgatga atgggagcag tgggaaatg ccttaatga ggaaaaacctg 600
20 ttttgetcag aagaatgcc atctagtgat gatgaggcata ctgctgactc tcaacattct 660
actccctccaa aaaagaagag aaaggttagaa gaccccaagg actttccctc agaattgcta 720
agtttttgta gtcatgtgt gttagtaat agaactcttgc tttgtttgc tatttacacc 780
acaaaaggaaa aagctgeact gctataacaag aaaattatgg aaaaatatttc tgtaacctt 840
ataagtaggc ataacagtta taatcataac atactgttt ttcttactcc acacaggcat 900
25 agagtgctg ctattaataa ctatgctcaa aaatgtgtt ccttttagctt tttaatttgt 960
aaagggttta ataaggaata ttgtatgtat agtgccttga cttagagatca taatcagcca 1020
taccacattt gtagagggtt tacttgcctt aaaaacccctc ccacacccctt ccctgaacct 1080
gaaacataaa atgaatgcaa ttgttgtgt taacttgcctt attgcagctt ataatggta 1140
30 caaaataaagc aatagcatca caaatttccac aaataaagca ttttttcac tgcattctag 1200
ttgtggtttg tccaaactca tcaatgtatc ttatcatgtc tggatccccca ggaagctct 1260
ctgtgtcctc ataaaccccta acctccctcta cttagagagga cattccaaatc ataggtgtcc 1320
catccacccct ctgtgtcctc ctgttaatta ggttaacttta caaaaaggaa attgggttagg 1380
40 ggtttttcac agaccgcctt ctaagggtaa tttaaaaata tctggaaagt cccttccact 1440
gctgtgttcc agaagtgttg gtaaacagcc cacaaatgtc aacagcagaa acataacaagc 1500
tgcagctt gcacaagggc ccaacccct gtcatacaag aagcaactgtg gttgtgtgt 1560
tagtaatgtg caaaacagga ggcacattt cccacactgt gtaggttcca aaatatctag 1620
tgttttcatt ttacttggta tcaggaaccc agcactccac tggataagca ttatccttat 1680
ccaaaacagc ttgtgttca gtgttcatct gtcactgtc aactgttagca ttttttgggg 1740
ttacagtttg agcaggatat ttggccctgt agttgtctaa cacaccctgc agtcaccaag 1800
45 gttccccacc aacagcaaaa aaatgaaaat ttgacccttg aatgggtttt ccagcaccat 1860
tttcatgagt tttttgtgtc cctgaatgca agtttaacat agcagttacc ccaataaccc 1920
cagtttaac agtaacagct tcccacatca aaatattcc acaggtaag tcctcattta 1980
aattaggcaa aggaatttctt gaagacgaaa gggcctcgta atacgcctat tttttaggt 2040
taatgtcatg ataataatgg ttcttagac gtcaggtggc acttttcggg gaaatgtgcg 2100
50 cgaaacccctt attgttttat ttcttaaat acattcaaat atgtatccgc tcatacgaca 2160
ataacccctga taaatgttcc aataatatttgc aaaaaggaaag agtatacgata ttcaacattt 2220
ccgtgtcgcc ttatccctt ttgtggc atttgcctt cctgttttttgc ttcacccaga 2280
aacgctggtg aaagtaaaag atgctgaaga tcagttgggt gcacgagtg 2340
actggatctc aacagcggta agatccttgc gagtttgc cccgaagaac gttttccaaat 2400
gatgagactt ttaaagttc tgctatgtgg cgcgttata tcccgtgttgc acgccccggca 2460
agagcaactc ggtcgccgca tacactattc tcagaatgac ttgggttgcgtt actcaccagt 2520
cacagaaaag catcttacgg atggcatgac agtaagagaa ttatgcagtg ctgcataac 2580
catgagtgat aacactgcgg ccaacttact tctgacaacg atcgaggac cgaaggagct 2640
55 aaccgctttt ttgcacaaca tggggatca tgtaacttgc cttgatcggtt gggaaaccgga 2700
gctgaatgaa gccataccaa acgacgagcg tgacaccacg atgcctgcag caatggcaac 2760

aacgttgcgc aaactattaa ctggcgaact acttactcta gcttccggc aacaattaat 2820
 agactggatg gaggcgata aagtgcagg accacccctg cgctcgccc ttccggctgg 2880
 ctggttatt gctgataaat ctggagccgg tgagcgtggg ttcgcggta tcattytcayc 2940
 5 actggggcca gatggtaagc cctccgtat cgtagttatc tacacgacgg ggagtcaaggc 3000
 aactatggat gaacgaaaata gacagatcgc tgagataggt gcctcaactga itaagcattg 3060
 gtaactgtca gaccaagttt actcatatat accttagatt gatttaaac ttcatttta 3120
 atttaaaagg atctaggtga agatccttt tgataatctc atgaccaaaa tcccttaacg 3180
 tgagttttcg ttccactgag cgtcagaccc cgtagaaaag atcaaaggat ttcttgaga 3240
 10 tcctttttt ctgcgcgtaa tctgtgtttt gcaaaacaaaa aaaccacccg taccagcggt 3300
 gttttgtttg ccggatcaag agctaccaac tcttttccg aaggtaactg gtttcagcag 3360
 agcgcagata ccaaatactg tccttctagt gtagccgtag tttaggccacc acttcaagaa 3420
 ctctgttagca ccgcctacat acctcgctt gctaattctg ttaccagtgg ctgctgccag 3480
 tggcgataag tcgtgtctta ccgggttggc ctcaagacga tagttaccgg ataaggcgca 3540
 15 gcggtcgggc tgaacggggg gttcgtgcac acagcccagc ttggagcga cgacctacac 3600
 cgaactgaga tacctacagc gtgagctatg agaaagcgcc acgtttcccg aaggagaaaa 3660
 ggcggacagg tatccgtaa gccggcagggt cggaacacgga gagcgcacga gggagcttcc 3720
 agggggaaac cccttgcattt ttatagttc tgtegggtt ccgcacccct gacttgagcg 3780
 tcgattttttgc ttagtgcgtt cagggggggc gagectatgg aaaaacgcga gcaacgcggc 3840
 20 ctttttaegg ttccctggcct ttgtgtggc ttttgcacat atgttctttc ctgcgttatac 3900
 ccctgattct gtggataacc gtattaccgc ctttgagtga gctgataaccg ctgcggcgag 3960
 ccgaacgcacc gagcgcagcg agtcgtgag cgaggaagcg gaagagcgcc tgatgcggta 4020
 ttttctctt acgcacatctgt gccgtattt acaccgcata tggtgcastc tcagtacaat 4080
 ctgctctgtat gcccataatg taagccagta tacactccgc tatcgctacg tgactgggtc 4140
 atggctgcgc cccgacaccc gccaacaccc gctgacgcgc cctgacgggc ttgtctgctc 4200
 25 ccggcatcccg cttacagaca agctgtgacc gtctccggga gctgcatgtg tcagaggttt 4260
 tcaccgtcat caccgaaacg cgcgaggcag ctgtgaatg tgggtgtgg 4320
 aagtccccag gctccccagc aggccagaatg atgcaagca tgcatctcaa tttagtcagca 4380
 accaggtgtg gaaagtcccc aggcctccca gcaggcagaa gtatgcaag catgcacatc 4440
 30 aattagtcaag caaccatagt cccgccttca actccccc tccccccct aactccccc 4500
 agttccgccc atttccgccc ccatggctga ctaattttt ttatttatgc agaggcccgag 4560
 gccgcctcgg cctctgagct attccagaag tagtgaggag gcttttttgg aggccttaggc 4620
 ttttgcaaaa agcttcacgc tgccgcaagc actcaggccg caagggctgc taaaggaagc 4680
 ggaacacgta gaaagccagt ccgcagaaac ggtgctgacc ccggatgaat gtcagctact 4740
 35 gggctatctg gacaagggaa aacgcacacg caaagagaaa gcaggttagct tgcagtggtc 4800
 ttacatggcg atagctagac tggcggtt tatggacagc aacgcacccg gaattgccag 4860
 ctggggcgcc ctctggtaag gttgggaagc cctgeaaagt aaactggatg gctttcttgc 4920
 cgccaaaggat ctgatggcgc aggggatcaa gatctgtatc agagacacgg tgaggatcgt 4980
 ttgcgtatgt tgaacaagat ggattgcacg cagggtctcc ggccgcttgg gtggagaggc 5040
 tattcggcta tgactggca caacagacaa tggctgctc tgatgcgc tggttccggc 5100
 40 tgcagcgca gggcgcccc gtttttttgc tcaagacccg cctgtccggt gccctgaatg 5160
 aactgcaggaa cgaggcagcg cggctatctgt ggctggccac gacggcggtt cttgcgcag 5220
 ctgtgctcga ctttgcact gaagcgggaa gggactggct gctattgggc gaagtgcggg 5280
 ggcaggatct cctgtcatct cacccgtct ctggcgagaa agtacccatc atggctgtatc 5340
 caatgcggcg gctgcatacg ctgtatccgg ctacccatc atcgaccac caagcgaaac 5400
 45 atcgcatcga gcgagcacgt actcggtatgg aagccggct tgcgtatcgt gatgatctgg 5460
 acgaagagca tcagggctc ggcgcacccg aactgttcgc caggctcaag ggcgcacatc 5520
 ccgcacggcga ggatctcgcc tgacccatc ggcgcacccg ctggccgaat atcatggtgg 5580
 aaaatggccg ctttctggta ttcatcgact gtggccggc ggggtgtggc gaccgcatac 5640
 50 aggcacatgc gttggctacc tgcgtatattt ctgaagagct tggcgccgaa tggctgacc 5700
 gcttcctctgt gcttacggt atcgccgcctc ccgatcgca ggcgcacatc ttctatcgcc 5760
 ttcttgacga gttcttctgt gggggactt ggggttcgaa tccctaccagg gattggctga 5820
 ctgtatgtatc cgtgaggacg aaacgaaaaa catatggtac 5860

<210> 6

<211> 4610

<212> DNA
<213> Influenza virus

ttccccgcaaa caattaatag actggatgga ggcggataaa gttgcaggac cacttctgcg 3120
 ctggccctt ccgcgtcgct ggtttattgc tgataaaatct ggagccggtg agcgtgggtc 3180
 tgcgggtatc attgcac cac tggggccaga tggtaagccc tcccgatcg tagttatcta 3240
 cacgacgggg agtcaggca astatggatga acgaaataga cagatcgctg agataggtgc 3300
 5 ctcaactgatt aagcatttgt aactgtcaga ccaagttaac tcataatatac ttttagattga 3360
 tttaaaactt cattttaat taaaaggat ctaggtgaag atccttttg ataatctcat 3420
 gacaaaatc ccttaacgtg agttttcggtt ccactgagrg ttagacccccc tagaaaaagat 3480
 caaaggatct tctttagatc cttttttct gcgcgtatc tgctgcttgc aaacaaaaaaa 3540
 10 accaccgcta ccagcgggtgg tttgtttgcc ggatcaagag ctaccaactc ttttccgaa 3600
 ggtaactggc ttcagcagag cgccagatacc aaataactgtc cttctagtgt agccgttagt 3660
 aggccaccac ttcaagaact ctgttagcacc gcctacatac ctcgcctctgc taatccctgtt 3720
 accagtggct gctgccagtg gcgataagtc gtgtcttacc gggttggact caagacgata 3780
 gttaccggat aaggcgcgc ggtcgggctg aacggggggt tctgtcacac agcccaagctt 3840
 15 ggagcgaacg acctacaccg aactgagata cctacagcgt gagctatgag aaagcgcac 3900
 gcttcccgaa gggagaaaagg cgacaggta tccggtaagc ggcagggtcg gaacaggaga 3960
 ggcacgagg gagcttccag ggggaaacgc ctggtatctt tatagtccctg tcgggtttcg 4020
 ccacctctga cttgagcgtc gattttctg atgctgtca gggggcggaa gcctatggaa 4080
 aaacgccagc aacgcggctt ttttacgggtt cctggcttt tgctggcctt ttgctcacat 4140
 20 gttcttctt gcttatccc ctgattcatt aatgcaggta acgatccctt ctggcgagtc 4200
 cccgtcgcca gtcggagacg gctccctgag cgctgcggc cccgagaggac ggcctggcc 4260
 ggccttcggt ccctcggtg tcccggtcg aggaggggcc gggcgaaaat gcttcccgct 4320
 cccgcctctgg agacacgggc cggccccctg cgtgtggcac gggcgcccg gggggcgcc 4380
 25 cccggccccc yctyctcccg cgtgtgtctt ggggttgacc agagggcccc gggcgctccg 4440
 tgtgtggctg cgtatggtgc gtttttgggg acaggtgtcc gtgtccgtgt cgccgcgtcg 4500
 ctggggccccc ggcgtggctg gtacgcgac ctccggcccc cggggggaggt atatcttcg 4560
 ctccgagtcg gcatttttggg cccgggggtt attagtagaa acaggggtac 4610

<210> 7
 <211> 3558
 30 <212> DNA
 <213> Influenza virus

<400> 7

tattagtaga aacagggtat ttttattct agtacattac gccccggccct gccactcatc 60
 35 gcaagtactgt tgtaattcat taagcattct gccgacatgg aagccatcac agacggcatg 120
 atgaacctga atcggccagcg gcatcagcac cttgtcgccct tgcgtataat atttgcctat 180
 ggtgaaaacg ggggcaaga agttgtccat attggccacg tttaaatcaa aactggtgaa 240
 actcaccctcg ggtatggctg agacaaaaaa catattctca ataaaccctt tagggaaata 300
 40 ggccaggttt tcacgtaac acgccacatc ttgcgaatat atgtgttagaa actgcccggaa 360
 atcgctgtgg tattcactcc agagcgtatga aaacgttca gtttgcgtcat gggaaacgg 420
 gtaacaaggg tgaacactat cccatatac cagctccacccg tctttcatttgc ccatacgaa 480
 ttcggatga gcatcatac ggcgggcaag aatgtgaata aaggccggat aaaacttgc 540
 45 ctatattttc ttacggctt tttaaaaggc cgtaataatcc agctgaacgc tctggttata 600
 ggtacatgtg gcaactgact gaaatgcctc aaaatgttct ttacgtatgc attggatata 660
 atcaacgggtg gtataccatc tgatttttt ctccatgatt atggccattt cccttgcgtt 720
 tactcccccc caacttcgga ggtcgaccag tactccggc gaaactttgt tttttttttt 780
 tccccccatg ctggaggtcg accagatgtc cgaaagtgtc ccccccccccc ccccccccccg 840
 50 ggcggaaacg gccccccac tctggactt tttttttttt tttttttttt tttttggga 900
 tcggccgcta gcttctgttt tggcggtatga gagaagatcc tcaagcctgtat acagataaa 960
 tcagaacgcg gaagcggtct gataaaaacag aatggccctg gccggcgttag cgccgtggtc 1020
 ccacctgacc ccatggcaaa ctcagaagtgc aaacggcgta ggcggatgg tagtgtgggg 1080
 tctccccatg cgagagtagg gaaactggccag gcatcaaata aaacgaaagg ctcagtcgaa 1140
 agactggcc tttcggtttt tctgttgcgtt gtcggtaac gctctccatgat gtaggacaaa 1200
 tccggccggga gcggttttgc acgttgcgaa gcaacggccc ggaggggtggc gggcaggacgg 1260
 55 cccggccataaa actggccagggc atcaaattaa gcagaaggcc atccgtacgg atggccctttt 1320

5 tgcgtttcta caaaactcttt tgtttatttt tctaaataca ttcaaataatg tatccgctca 1380
 tgagacaata accctgataa atgcttcataat aatattgaaa aaggaagagt atgagtattc 1440
 aacatttccg tgcggccctt attccctttt ttgcggcatt ttgccttcct gtttlyctc 1500
 acccagaaaac gctgggtgaaa gtaaaagatg ctgaagatca gttgggtgca cgagtgggtt 1560
 acatcgaaact ggatctcaac agcggttaaga tccttgagag ttttcgcccc gaagaacgtt 1620
 ttccaatgtat gaggactttt aaagtttgc tatgtggcgc ggtattatcc cgtgttqacg 1680
 ccggggcaaga gcaactrsgt cgccgcatac actatttcataa gaatgacttg gttgagtaact 1740
 caccagtcaac agaaaagcat cttacggatg gcatgacagt aagagaatta tgcagtgc 1800
 ccataaccat gaggataaac actgcggcca acttacttct gacaacgcate ggaggaccga 1860
 aggagcttaac cgctttttt cacaacatgg gggatcatgt aacttcgcctt gatcggttggg 1920
 aaccggagct qaataqaaagcc atacccaaacg acgagcgtga caccacgatg cctgttagcaa 1980
 tggcaacaac gttgcgcaaa ctattaactg gcaactact tactctagct tcccgcaac 2040
 aattaataga ctggatggag gcggataaaag ttgcaggacc acttctgcgc tcggcccttc 2100
 cggctggctg gtttatttgc gataaatctg gagccggatg gcgtgggtct cgcgttatca 2160
 ttgcagcaact ggggccagat ggtaagccct cccgtatctg agttatctac acgacgggga 2220
 gtcaggaacat tattggatgaa cgaaatagac agatcgctga gataggtgcc tcactgatta 2280
 agcattggta actgtcagac caagttact catataact ttagattgtat taaaacttc 2340
 attttttaatt taaaaggatc taggtgaaga tccttttga taatctcatg accaaaatcc 2400
 cttAACGTGA gtttctgttc cactgagctg cagacccccgt agaaaagatc aaaggatctt 2460
 ctttagatcc ttttttctg cgcgtaatct gctgcttgc aaaaaaaaaa ccaccgtac 2520
 cagcggttgt ttgtttgcgc gatcaagagc taccatctt ttttccgaag gtaactggct 2580
 tcagcagagc gcagatacca aatactgtcc ttctatgtat gccgtatgtt ggccaccact 2640
 tcaagaactc tgttagcaccc cctacatacc tegetctgtt aatccctgtt ccagtggctg 2700
 ctgccagtgg cgataagtctg tgcgttaccg gggtggactc aagacgatac ttaccggata 2760
 25 aggccgcacgc gtcgggctga acgggggggtt cgtgcacaca gcccgatctg gagegaacga 2820
 cctacaccga actgagatac ctacagcgatg agctatgaga aagcgccacg cttcccgaag 2880
 ggagaaaaggc ggacaggtat ccggtaagcg gcagggtcgg aacaggagag cgacgcgggg 2940
 agcttccagg gggaaacgccc tggtatctt atagtcctgt cgggttctgc cacctctgac 3000
 30 ttgagcgctg atttttgtga tgcgtcgatg gggggcggag cctatggaaa aacgccagca 3060
 acgcggccctt ttaacggttc ctggcctttt gctggctt tgctcacatg ttctttctg 3120
 cgtttatcccc tggatcatta atgcaggatca cgatcccttc tggcgagatcc cctgtcgagg 3180
 tcggagagcg ctccctgagc gcgtgcggcc cgagaggatcg cgccctggccg gccttcggc 3240
 cctcgtgtgt cccggctgtat gggggggccg gccgaaaatg ctccggctc cctgtctggaa 3300
 gacacggggcc ggccccctgc gtgtggcactg ggcggccggg agggcgctcc cggcccccggc 3360
 35 ctgctcccgcc gtgtgtctgt ggggttgcacca gagggccccg ggcgcctccgt gtgtggctgc 3420
 gatgggtggcg tttttgggaa caggtgtccg tgcgtgtatc ggcgcgtcgc tggggccggcg 3480
 gcgtggctgg tgaacgcgacc tcccgcccccc gggggaggtt tatcttcgc tccgagtcgg 3540
 cattttgggc cgccgggt 3558

40 <210> 8
 <211> 4343
 <212> DNA
 <213> Influenza virus

45 <400> 8
 ctttctggcg agtccccgtg cggagtcgga gagcgctccc tgagcgcgtg cggccccgaga 60
 ggtcgccctt ggccggccctt cggcccttcgt tggatccctgg tgcgttaggagg ggccggccga 120
 aaatgctcc ggctcccgct ctggagacac gggccggccc cctgcgtgtg gcacggggcgg 180
 cccggagggc gtccccggcc cggcgctgtt cccgcgtgtg tccctgggggtt gaccagaggg 240
 ccccccggcc tccgtgtgtg gctgcgtatgg tggcggtttt ggggacaggt gtccgtgtcc 300
 gtgtcgcccg tgcgttcggc cggccggcgatg tgcgtgtatgg cgacccctccg gccccgggggg 360
 aggtataatct ttcgtccga gtcggcattt tggggccgg ggttattatgt agaaacacaggg 420
 tatttttat actagtaagc tcgaaggatg ccaccatgatg taaaggagaaa gaacttttca 480
 55 ctggagttgtt cccaaatttctt gttgaattatg atggatgtt taatgggcac aaattttctg 540
 tcagtgaggaa ggggtgaaggtt gatgcacat acggaaaaact tacccttaaa tttatgtca 600

	ctactggaaa	actacacctgtt	ccatggccaa	cacttgcac	tactttcact	tatgggtttc	660
5	aatgctttc	aaagataccca	gatcatatga	aacagcatga	cttttcaga	agtggccatgc	720
	ccgaagggtta	tgtacaggaa	agaactatat	tttcaaaga	tgacgggaaac	tacaagacac	780
	gtgctgaagt	caagttgaa	ggtgatcaccc	ttgttaatag	aatcgagttt	aaaggatttt	840
	attttaaaga	agatggaaac	atttttgac	acaaatttgg	atacaactat	aactcacaca	900
10	atgtatacat	catggctgac	aagcagaaga	acggaatcaa	ggccaacttc	aagaccggcc	960
	acaacatcga	ggacggcgcc	gtgcagctgg	ccgaccacta	ccagcagaac	accccaattt	1020
	gcatggccc	tgtcccttta	ccagacaacc	attacctgtc	cacacaatct	gcccctttcga	1080
	aagatcccaa	cgaaaagaga	gaccacatgg	tccttcttga	gtttgttaaca	gtctgtggaa	1140
	ttacacatgg	catggatgaa	ctatacaagg	gatccccatca	ccatcaccat	cactaagctc	1200
	catggcttag	atatcttagt	cattacgccc	cgccctgcca	ctcatcgag	tactgttgta	1260
15	attcattaag	cattctgccc	acatggaaac	catcacagac	ggcatgtga	acctgttatcg	1320
	ccagcggcat	cagcaccttgc	tcgccttgcg	tataatattt	gcccattgtt	aaaacggggg	1380
	cgaagaagtt	gtccatatttgc	gccacgttta	aatcaaaaact	gtgttttttgc	acccagggtat	1440
	tggcactcact	aaagaacatcg	ttctcgatga	atcttttagg	gaagttaggc	aggttttac	1500
	cgtaacacgc	cacatcttgc	gaatataatgt	gtagaaacttgc	ccggaaatcg	tcgtgttatt	1560
20	cactccagag	cgatggaaac	gtttcagtttgc	gtttcatggaa	aacgggttac	caagggtgaa	1620
	cactatccca	tatcaccacgc	tcaccgttttgc	tcattgtccat	acggaaattcc	ggatgagcat	1680
	tcatcaggcg	ggcaagaatgt	tgaataaaagg	ccggataaaaa	tttgcgttta	tttttttttta	1740
	cggtctttaa	aaaggccgtt	atatccagct	gaacgggtctg	tttgcgttta	cattgagcaa	1800
	ctgactgaaa	tgcctcaaaa	tgttctttac	gtatccat	ggatataatca	acgggttat	1860
25	atccagtgat	ttttttctcc	atgattatgc	aaaaaaatacc	tttgcgttta	ctccccccca	1920
	acttccggagg	tgcaccagta	ctccggcga	aaatttttttgc	tttttttttgc	ccccgtatgt	1980
	ggaggtcgac	cagatgtccg	aaagtgtccc	cccccccccc	tttggggatc	ggccgttagc	2040
	ggggccactc	tggactcttttgc	tttttttttttgc	tttttttttttgc	tttggggatc	ggccgttagc	2100
	tttgcgttttgc	gcccgttgc	gaagatttttgc	agctgtatcc	agattaaatc	agaacgcaga	2160
	agccgttgc	taaaacagaa	tttgccttgc	ggcagtagcg	cggtgggttttgc	acctgtatccc	2220
30	atgcgaact	cagaagtgttgc	acgcgttgc	ggcgtatggta	gtgtgggttgc	tccccatgtcg	2280
	agagttaggaa	actgccttgc	atcaaataaa	acgaaaggct	cagtcgaaag	actgggcctt	2340
	tcgttttatac	tgttgcgttgc	cggtgaacgc	tctcctgttttgc	aggacaatcc	cgccgggagc	2400
	ggatttgaac	gttgcgttgc	aacggcccg	agggtggccgg	gcaggaccc	cgccatataac	2460
	tgccaggcat	caaattaatgc	agaaggccat	cctgacggat	ggcccttttgc	cggttttatac	2520
	aactcttttgc	tttatttttgc	taaatacatt	caaataatgttgc	tccgttccat	agacaataac	2580
35	cctgataaaat	gtttcaataaa	tattggaaaa	ggaagagtat	gagtatttac	catttccgttgc	2640
	tcgcctttat	tcccttttttgc	ggccatcccc	gccttcttgc	ttttgcgttac	ccagaaacgc	2700
	tggtggaaatgt	aaaagatgttgc	gaagatcgttgc	ttgggtgcac	agtgggttac	atcgaaacttgc	2760
	atctcaacag	cggttgcgttgc	tttgcgttgc	tttgccttgc	agaacgttttgc	ccaaatgttgc	2820
	gcactttttaa	agttctgttgc	tgtggccgg	tattatcccg	tgttgcgttgc	gggcaagagc	2880
40	aactccggatc	ccgcataccac	tattctcaga	atgactttgttgc	tgagtacttgc	ccagtcacag	2940
	aaaagcatctt	tacggatggc	atgacagtaa	gagaattatgc	cagtgttttgc	ataaccatgttgc	3000
	gtgataacac	tgccggccaaac	ttacttcttgc	caacgtatcc	aggaccgttgc	gagctaaccgc	3060
	tttttttgc	caacatgggg	gatcatgttgc	ctccgttgc	tgcgttggaa	ccggagcttgc	3120
	atgaagccat	accaaaccgc	gagcgttgc	ccacgtatcc	tgcgttggaa	ccggagcttgc	3180
	tgcgttggaa	atataacttgc	gaactacttgc	ctctgttttgc	ccggcaacaa	ttaatagacttgc	3240
45	ggatggggc	ggataaaatgttgc	gcaggaccac	tttgcgttgc	ggccctttcc	gctgggttgc	3300
	ttatttgc	taaatacttgc	gcccgttgc	gtgggttgc	cggttacat	gcagcaacttgc	3360
	ggccatgttgc	taagcccttgc	cgatgttgc	ttatcttgc	gacggggat	caggcaacttgc	3420
	tggatgttgc	aaatacttgc	atcggttgc	taggtgttgc	actgtttaatgc	catttgcgttgc	3480
	tgtcagatcc	atgttacttgc	tatataacttgc	agattgttgc	aaaacttcat	tttttttttgc	3540
50	aaaggatcttgc	ggtgttgcgttgc	tttttgcgttgc	atctcatgttgc	aaaatccat	taacgttgat	3600
	tttcgttccat	cttgcgttgc	tttgcgttgc	tttgcgttgc	aggatcttgc	tgagatcttgc	3660
	tttttgcgttgc	ctgttgcgttgc	tttgcgttgc	tttgcgttgc	accgttccat	gcccgttgc	3720
	gtttgcgttgc	tcaagatcc	ccaaacttgc	ttccgttgc	actgtttaatgc	agcagatgttgc	3780
	agataccaaa	tactgttgc	cttgcgttgc	tttgcgttgc	ccaccatcc	aagaacttgc	3840
55	tagcaccgc	tacataatcc	gttgcgttgc	tttgcgttgc	agtggttgc	ggccgttgc	3900

ataagtgcgtg tcttaccggg ttggactcaa gacgatagtt accggataag ggcgcggc 3960
 cgggcgtgaac ggggggggttcg tgcacacagc ccagcttggc gcaacgacc tacaccgaac 4020
 5 tgagataacct acagcgttag ctatgagaaa ggcgcacgc tccccaaagg agaaaggcgg 4080
 acaggatattcc ggttaaegggc agggtcgaa caggagagcg caagggggag cttccagggg 4140
 gaaacgcctg gtatctttat agtccgtcg ggtttcgcca cctctgactt gagcgtcgat 4200
 ttttgtatg ctcgtcaggg gggcgagcc tatggaaaaa cgccagcaac gggcccttt 4260
 tacggttctt ggcctttgc tggcccttttgc ctcacatgtt cttccgtcg ttatccccctg 4320
 attcattaaat gcaggtcact atc .: 4343

10 <210> 9
 <211> 3888
 <212> DNA
 <213> Influenza virus

15 <400> 9
 cccaaaaaaaaa aaaaaaaaaa aaaaaaaaaa agtccagagt ggcccccggc ttccgcggc 60
 gggggggggg gggggggggg cacttcggc catctggcg acctccagca tcggggggaaa 120
 aaaaaaaaaac aaagtttgc cgggactt ggtgcaccc cgaagttggg ggggagtaga 180
 20 aacagggttag ataatcactc actgagtgac atccacatcg cgagcgcgc taatacact 240
 cactataggg cgaattgggt accggcccc cccctcgaggt cgacggatc gataagctc 300
 gacgagattt tcaggagcta aggaagctaa aatggagaaa aaaatcaactg gatataccac 360
 cgttgatata tcccaatggc atcgtaaaga acatttttagt gcatttcagt cagttgtca 420
 atgtacccat aaccagaccc ttcagctggc tattacggcc ttttaaaga cctgaaagaa 480
 25 aaataaagcac aagttttattc cggcccttta tcacattttt gcccgcctga tgaatgtca 540
 tccggaattc cgtatggcaa tgaaagacgg tgagctggc atatggata gtgttcaccc 600
 ttgttacacc gttttccatg agcaaactga aacgttttca tcgctctggc gtgaatacca 660
 cgacgattt cggcagttt tacacatata ttcgcaagat gtggcggtt acgtgaaaaa 720
 cctggccat tttccctaaag ggtttattga gaatatgtt ttcgtctcag ccaatcccc 780
 30 ggtgagtttcc accagttttt atttaaacgt ggcacatatg gacaacttcc tcgccccgt 840
 tttcaccatg ggcaaatatt atacgcaagg cgacaagggtg ctgatgccgc tggcgattca 900
 ggttcatcat gccgtttgtg atggcttcca tgcggcaga atgcttaatg aattacaaca 960
 gtactgcgt gagtggcagg gcggggcgta atttttttaa ggcagttatt ggtgcctta 1020
 aacgcctggt gctacgcctg aataagtgt aataagcggg tgaatggcag aaattcgtcg 1080
 35 aagcttgata tgcattttcc gcagccccggg ggatccacta gttctagagc ggccgcacc 1140
 gcggtggagc tccagttttt gttccctta gtgggggtt attgcgcga ggcttagcta 1200
 ggttaaagaaa aatacccttg attttctaa taaccggcg gcccggaaatg cgcactcg 1260
 gcgaaagata tacctcccccc gggggcggga ggtgcgtca cgcaccazgc cgccggccca 1320
 ggcgacgcgc gacacggaca cctgtccccca aaaacgcac catgcacgac acacacggag 1380
 40 cccccggggc cctctggc accccgaggac acacgcggga gcagcgcgg gccccggacg 1440
 ccctccggc cggccgtgcc acacgcaggc gggccggcccg tgcgtccaga gcggagccg 1500
 gaagcatttt cggccggccc ctcctacgac cgggacacac gagggacccg agggccggcc 1560
 ggcgacgcct ctcggggccgc acgcgcgtc agggagcgct ctccgactcc gcacggggac 1620
 tcgccagaaa ggtatgtac ctgcattaaat gaatcgggg ataacgcagg aaagaacatg 1680
 tgagaaaaag gccagaaaaa ggccaggaac cgtaaaaagg cgcgttgc ggcgttttc 1740
 45 cataggctcc gccccccctga cgagcatcac aaaaatcgac gtcacgtca gaggtggcga 1800
 aacccgacag gactataaaag ataccaggcg ttccccctg gaagctccct cgtgcgtct 1860
 cctgtccga ccctgcgcgt taccggatac ctgtccgcct ttctccctt gggaaagcggt 1920
 ggcgttctc atagctcactg ctgttaggtat ctcagttcg tgcgttgc tgcgtccaaag 1980
 50 ctgggtgtg tgcacgaacc ccccggtcag cccgaccgc ggcgccttac cgtaactat 2040
 cgtcttgcgtt ccaacccgggt aagacacgcac ttatgcgcac tggcagcagc cactggtaac 2100
 aggatttagca gagcgggtt tgcgttgcgtt gtcacagagt tcttgaatg gtggcctaaac 2160
 tacggctaca cttagaaggac agtatttggt atctgcgcctc tgctgaagcc agttacctt 2220
 gaaaaaagag ttggtagctc ttgatccggc aaacaaaacca cgcgtggtag cggtgggtt 2280
 tttgttgcgtt ggcgttgcgtc tgcgttgc tgcgttgc gaaaactcactt gtttggat 2340
 55 tttctacgg ggcgttgcgtc tgcgttgc tgcgttgc gaaaactcactt gtttggat tttgttgcgtt 2400

agattatcaa aaaggatctt cacctagatc cttttaaatt aaaaatgaag ttttaaatca 2460
 atctaaagta tatatgagta aacttggtct gacagttacc aatgtttaat cagtggggca 2520
 cctatcttag cgatctgtct atttcggttca tccatagttg cctgactccc cgtcgtgtag 2580
 5 ataactacga tacgggaggg cttaccatct ggccccagtg ctgcaatgt accgcgagac 2640
 ccacgctcac cggtccaga ttatcagca ataaaccaggc cagccgaaag ggccgagcgc 2700
 agaagtggtc ctgcaacttt atccgcctcc atccagtcta ttaattgttg ccggaaagct 2760
 agaytaagta gttcgccagl taatagttt cgcaacgttg ttgccattgc tacaggcgc 2820
 gtgggtcac gctcgctgtt tggtatggct tcattcagct ccggttccca acgatcaagg 2880
 10 cgagttacat gatccccat gttgtgcaaa aaagcggtta gtccttcgg tcctccgatc 2940
 gttgtcagaa gtaagttggc cgccagtttca tcactcatgg ttatggcagc actgcataat 3000
 tctcttactg tcatgccatc cgtaagatgc ttttctgtga ctgggtgagta ctcaaccaag 3060
 tcattcttag aatagtgtat gcggcgaccc agttgtctt gcccggcgtc aacacgggat 3120
 aataccgcgc cacatagcag aactttaaa gtgcctcatca ttggaaaacg ttcttcgggg 3180
 15 cgaaaaactct caaggatctt accgctgtt agatccagtt cgatgttacc cactcgatc 3240
 cccaaactgtat cttcagcattc ttttactttc accagcgttt ctgggtgagc aaaaacagga 3300
 aggccaaaatg ccgcaaaaaaaaa gggataaagg ggcacacggg aatgttgaat actcataactc 3360
 ttccttttc aatattattt aagcattttt cagggttatt gtctcatgg cgatcataata 3420
 tttgaatgtt ttttagaaaaaa taaacaaaaag agtttgtaga aacgcaaaaaaaaa ggccatccgt 3480
 20 caggatggcc ttctgtttaa tttgtatggctt ggcagtttat ggccggcggtc ctggccggcca 3540
 ccctccgggc cggtgttccg caacgttcaa atccgttccca ggcggatttg tcctactcag 3600
 gagagcggttc accgacaaaac aacagataaa acgaaaggcc cagttttcg actgaggctt 3660
 tcgttttatt tgatggctgg cagttcccta ctctcgcatg gggagacccc acaactaccat 3720
 cggcgctacg gcgtttcact tctgagttcg gcatggggtc aggtgggacc accgcgtac 3780
 25 tgccgcagg caaattctgt tttatcagac cggttctgcg ttctgattta atctgtatca 3840
 ggctgaaaat cttctctcat ccgcggaaaac agaagcttagc ggccgatc 3888

30

35

40

45

50

55

Claims

1. A recombinant influenza virus for high-yield expression of incorporated foreign gene(s), which is genetically stable in the absence of any helper virus; wherein
 - 5 (a) at least one of the regular viral RNA segments has been exchanged for a vRNA encoding a foreign gene; and/or
 - (b) at least one of the regular viral RNA segments is an ambisense RNA molecule, containing one of the standard viral genes in sense orientation and a foreign, recombinant gene in anti-sense orientation, or vice versa, in overall convergent arrangement.
2. The recombinant virus according to claim 1, wherein in the ambisense RNA molecule said foreign recombinant gene is covalently bound to one of the viral genes, while the original vRNA segment coding for the same gene is deleted from the recombinant virus by way of specific ribozyme cleavage.
3. The recombinant virus according to claims 1 and 2 in which one or both of the standard glycoproteins hemagglutinin and neuraminidase have been exchanged into foreign glycoprotein(s) or into fusion glycoproteins consisting of an anchor segment derived from hemagglutinin and an ectodomain obtained from the foreign source, viral or cellular, or in which such recombinant glycoprotein has been inserted as a third molecular species in addition to the remaining standard components.
4. The recombinant virus according to claims 1 to 3, in which the terminal viral RNA sequences, which are active as the promoter signal, have been varied by nucleotide substitutions in up to five positions, resulting in improved transcription rates of both the vRNA promoter as well as the cRNA promoter as present in the complementary sequence.
5. The recombinant virus according to claims 1 to 4, in which the foreign gene(s) in ambisense covalent junction with viral gene(s) code for proteins and/or glycoproteins which are secreted from cells infected with the recombinant virus.
6. The recombinant virus according to claims 1 to 4, in which the foreign gene(s) in ambisense covalent junction with viral gene(s) code for proteins or artificial polypeptides designed to support an efficient presentation of inherent epitopes at the surface of (abortively) infected cells, for stimulation of a B cell and /or T cell response.
- 35 7. A method for the production of recombinant influenza viruses as defined in claims 1 to 6 comprising
 - (a) RNA polymerase I synthesis of recombinant vRNAs *in vivo*, in antisense, sense or ambisense design,
 - (b) followed by infection with an influenza carrier strain constructed to include flanking ribozyme target sequences in at least one of its viral RNA segments, and
 - (c) thereafter selective vRNA inactivation through ribozyme cleavage.
8. A method of constructing influenza carrier strains carrying one or more ribozyme target sites (of type one) in vRNA flanking positions comprising
 - 45 (a) RNA polymerase I synthesis of recombinant vRNAs *in vivo*, carrying two different 3' promoter sequences in tandem, which are separated by a second type of ribozyme target sequence, and which carry the said internal ribozyme target sites of type one;
 - (b) followed by infection of an influenza wildtype strain;
 - (c) thereafter amplification through simple steps of viral propagation; and
 - (d) finally isolation through removal of their external 3' promoter sequence by ribozyme cleavage through infection of cells expressing ribozyme type 2, followed by plaque purification.
 9. A ribozyme-sensitive influenza carrier strain obtainable by the method of claim 8.
 - 55 10. A pharmaceutical composition comprising a recombinant virus according to claims 1 to 6.
 11. Use of a recombinant virus according to claims 1 to 6 for preparing a medicament for vaccination purposes.

12. The use according to claim 11, wherein the medicament

- 5
(a) is suitable against influenza and/or against other infections;
(b) is present in form of inactivated preparations; and/or
(c) is present in form of live recombinant (attenuated) viruses.

10
13. Use of a recombinant virus according to claims 1 to 6 as vector systems in somatic gene therapy, for transfer and expression of foreign genes into cells (abortively) infected by such viruses, either in *ex vivo* or *in vivo* application schemes.

14. A method for the production of proteins or glycoproteins which comprises utilizing a recombinant influenza virus according to claims 1 to 6 as expression vector.

15
15. The method of claim 14, wherein the production is performed in cell culture cells or in fertilized chicken eggs.

20

25

30

35

40

45

50

55

FIG. 1




FIG. 2




FIG. 3




FIG. 4




FIG. 5




FIG. 6




FIG. 7




FIG. 8




FIG. 9




FIG. 10





FIG. 11



bp-variant position \	G - C	A - U	C - G	U - A
2 - 9	pII.2024 100%	pII.1921 41%	pII.2003 < 3%	pII.2004 < 3%
3 - 8	pII.2002 30%	pII.1920 121%	pII.1148 39%	pII.2024 100%
2 - 9	pII.1945 11%	pII.1946 30%	pII.2024 100%	pII.1923 28%
3 - 8	pII.2428 6%	pII.2024 100%	pII.1948 33%	pII.1922 97%




FIG. 12




FIG. 13




FIG. 14




FIG. 15




FIG. 16




FIG. 17




FIG. 18




FIG. 19





FIG. 20





European Patent
Office

PARTIAL EUROPEAN SEARCH REPORT

Application Number

which under Rule 45 of the European Patent Convention EP 99 10 4519
shall be considered, for the purposes of subsequent
proceedings, as the European search report

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION
X	DE 197 09 512 A (HOBOM GERD PROF DR DR) 10 September 1998 (1998-09-10)	1,3,4, 7-14	C12N15/86 C12N7/01
Y	* the whole document *	2,5,6,15	C12N5/10 A61K39/00
X	WO 91 03552 A (SINAI SCHOOL MEDICINE) 21 March 1991 (1991-03-21)	1,10-15	A61K39/145
Y	* figure 11; example 7 *	2,5,6	A61K48/00
Y	TAKASE H. ET AL: "Antibody responses and protection in mice immunized orally against influenza virus." VACCINE, vol. 14, no. 17/18, 1996, pages 1651-1656, XP002110225 * page 1652, left-hand column, paragraph 1 *	15	
X	ZHOU Y. ET AL.: "Membrane-anchored incorporation of a foreign protein in recombinant Influenza virions." VIROLOGY, vol. 246, 20 June 1998 (1998-06-20), pages 83-94, XP002110226 * the whole document *	1,10-14	
	-/-		
INCOMPLETE SEARCH			
The Search Division considers that the present application, or one or more of its claims, does/do not comply with the EPC to such an extent that a meaningful search into the state of the art cannot be carried out, or can only be carried out partially, for these claims			
Claims searched completely:			
Claims searched incompletely:			
Claims not searched:			
Reason for the limitation of the search: see sheet C			
Place of search	Date of completion of the search	Examiner	
THE HAGUE	26 July 1999	Mandl, B	
CATEGORY OF CITED DOCUMENTS		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons -/- S : member of the same patent family, corresponding document	
X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document			



European Patent
Office

INCOMPLETE SEARCH
SHEET C

Application Number
EP 99 10 4519

Although claim 13 and claim 14, as far as an in vivo application is concerned, are directed to a method of treatment of the human/animal body (Article 52(4) EPC), the search has been carried out and based on the alleged effects of the compound/composition.



European Patent
Office

PARTIAL EUROPEAN SEARCH REPORT

Application Number
EP 99 10 4519

DOCUMENTS CONSIDERED TO BE RELEVANT		Relevant to claim	CLASSIFICATION OF THE APPLICATION
Category	Citation of document with indication, where appropriate, of relevant passages		
X	PALESE P. ET AL.: "Negative-strand RNA viruses: Genetic engineering and applications." PROC. NATL. ACAD. SCI. U.S.A., vol. 93, October 1996 (1996-10), pages 11354-11358, XP000196755 * page 11354, right-hand column, last paragraph - page 11356, right-hand column, paragraph F * ----- ZOBEL A. ET AL.: "RNA polymerase I catalysed transcription of insert viral cDNA." NUCLEIC ACIDS RESEARCH, vol. 21, no. 16, 1993, pages 3607-3614, XP002110227 * page 3607, right-hand column, paragraph 2 * * page 3612, right-hand column, paragraph 2 - page 3613, left-hand column, line 1 * * page 3614, left-hand column, paragraph 2 * ----- 	1,10-14	
X		1,10	TECHNICAL FIELDS SEARCHED

**ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.**

EP 99 10 4519

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report.
The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

26-07-1999

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
DE 19709512 A	10-09-1998	NONE		
WO 9103552 A	21-03-1991	US 5166057 A	24-11-1992	
		AT 126272 T	15-08-1995	
		AU 636916 B	13-05-1993	
		AU 6411890 A	08-04-1991	
		CA 2065245 A	01-03-1991	
		DE 69021575 D	14-09-1995	
		DE 69021575 T	14-12-1995	
		DK 490972 T	30-10-1995	
		EP 0490972 A	24-06-1992	
		ES 2075901 T	16-10-1995	
		GR 90100639 A	30-12-1991	
		JP 5500607 T	12-02-1993	
		PT 95124 A	18-04-1991	
		US 5252289 A	12-10-1993	
		US 5578473 A	26-11-1996	
		US 5854037 A	29-12-1998	
		US 5840520 A	24-11-1998	
		US 5786199 A	28-07-1998	
		US 5820871 A	13-10-1992	